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CHAPTER 1: INTRODUCTION
1.1 Activation- Induced Deaminase
Maintaining sequence fidelity of the genetic information coded in
deoxyribonucleic acid (DNA) is essential to the development and function of
organisms because inadvertent sequence changes may result in adverse
consequences to the cell, daughter cells, and the organism. Accordingly, many
DNA repair processes have evolved to preserve the genome during normal
cellular processes such as replication. Although there exists immense pressure
to protect against genomic instability and corruption of sequence context,
beneficial programmed alterations to genomic DNA which lead to sequence
changes do occur in specialized processes of the adaptive immune system.
Through targeted mutations of the immunoglobulin gene of B cells, activationinduced deaminase (AID) equips the adaptive immune system with the capability
of producing a diverse repertoire of antibodies against an almost infinite number
of antigens and pathogens. However, this mutagenic potential of AID can also be
deleterious to B cells if it is ectopically expressed, fostering the possibility for
genomic instability. The focus of this research is to quantify the DNA lesions
introduced by AID in normal and cancerous B cell genomes for the first time, and
track the unfavorable consequences that may arise from the aberrant activity of
AID which may promote development of B cell lymphomas.
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1.1.1 The Discovery of AID and its Requirement for Antibody Maturation
AID was discovered in 1999 in the murine B cell lymphoma cell line
CH12F3 (1) which was isolated as a model for class switch recombination (CSR),
a mechanism required to make the antibody isotype most fit for a specific
category of antigens (see section 1.2.4 for further details). Specifically, CH12F3
cells class switch from IgM isotype to IgA when stimulated with a particular
cocktail of cytokines (CD40L, IL-4, TGF-β or ‘CIT’). Honjo and colleagues
investigated the genes with upregulated expression upon CIT stimulation of
CH12F3 cells using suppression subtractive hybridization (SSH) (2). This PCRbased method allowed for the amplification of only complementary DNA (cDNA)
that differed between the transcriptome of stimulated cells and unstimulated
cells. AID expression was found to be highly induced only when cells were
stimulated to undergo CSR.
A role for AID in the maturation of antibodies was immediately attractive
due to its largely restricted tissue expression in activated B cells (2). Critical
supportive evidence of AID’s role in antibody maturation was the finding that
CSR and somatic hypermutation (SHM), a second mechanism required for
antibody affinity maturation (see section 1.2.3 for further details), were both
abolished in mice with a homozygous deficiency in AID (3). Concomitantly,
Durandy and colleagues determined that patients with hyper-IgM syndrome
(HIGM2), where CSR and SHM are found to be defective, had mutations in the
human gene encoding for AID (4). Thus, AID is indispensable for CSR, SHM,
and antibody affinity maturation.
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1.1.2 AID and the Deamination of Cytosine to Uracil in DNA
Honjo et al explored the ability of a GST-AID fusion protein to deaminate
cytidine in vitro since early sequence alignment studies revealed homology of
AID to Apolipoprotein-B mRNA editing enzyme catalytic polypeptide-1 (APOBEC1, 34% amino acid identity). APOBEC-1 was the only well-characterized
APOBEC family member at the time (2) and since it was known to be an RNA
editor that deaminates cytidine to uracil in the mRNA of apolipoprotein-B (5), it
was logically proposed that AID similarly functioned by editing an unknown
mRNA substrate to indirectly lead to CSR and SHM. However, this mRNA-editing
model of AID in adaptive immunity is not supported by the vast majority of
evidence in the field.
The ectopic expression of AID in eukaryotic cells such as hybridomas (6),
T cells (7), fibroblasts (8), and yeast (9) resulted in mutations at cytosines in their
genomic DNA. Similarly, ectopically expressing AID in E. coli resulted in
mutations at cytosines in the genome and AID-dependent mutations were further
enhanced in E. coli deficient in uracil-DNA glycosylase (UNG), the primary
enzyme that removes uracils in DNA (10). AID is not naturally present in
prokaryotes such as E. coli, but its ability to promote mutations in the E. coli
genome suggested that an mRNA intermediate was unlikely the substrate for AID
in B cells. Based on these E. coli studies, Petersen-Mahrt et al envisioned a
model where AID directly deaminates cytosines in DNA to uracil specifically in
the Ig locus of B cells (see Figure 1). Pathways for SHM and CSR were
hypothesized to occur from the processing of these uracils by other downstream
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enzymes such as UNG2, error-prone polymerases, mismatch repair (MMR)
proteins, and AP endonuclease (10).
Figure 1: AID Dependent Hydrolytic Deamination of Cytosine to Uracil

2’deoxycytidine

AID

2’ deoxyuracil

Deamination

Figure 1: AID Dependent Hydrolytic Deamination of Cytosine to Uracil. AID
catalyzes the nucleophilic attack of a water molecule at the C4 position of
cytosine. The loss of the amino group as ammonia, results in the formation of
uracil. Figure created in ChemBioDraw Ultra 14.0.
Several groups provided biochemical evidence that supports DNA,
specifically single-stranded DNA or single-stranded regions in transcribed
double-stranded DNA, as the substrate for AID cytosine deamination. AID was
shown not to deaminate cytosines in RNA, non-transcribed double-stranded
DNA, or DNA-RNA hybrids (11-14). Furthermore, in vitro studies determined that
the hotspot for AID deamination is a cytosine occurring in a WRC motif (where W
is an A or T, R is a purine, ie G or A) (15). This is in agreement with the WRC
SHM hotspot motif determined in vivo (15). Substantial evidence in the field has
predominantly supported the direct ‘DNA-editing model’ of AID at the Ig gene,
and thus this model prevails over the originally proposed ‘mRNA editing model’. It
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is widely accepted that AID catalyzes the hydrolytic deamination of 2’deoxycytidine (C) to 2’-deoxyuracil (U) in a sequence context specific manner
and prefers single-stranded DNA regions in the Ig gene (see Figure 1) (16).
Figure 2: The Primary Structure of AID

AID: Human Chromosome 12

Figure 2: The Primary Structure of AID. AID is found on human chromosome
12 and has 5 exons. The gene codes for a 198 amino acid protein. The primary
structure of AID is depicted above with major domains of the protein highlighted.
AID has an amino terminal nuclear localization signal (NLS), and a carboxy
terminal nuclear export signal (NES). The catalytic domain is required for both
somatic hypermutation (SHM) and class switch recombination (CSR). Catalysis
of the hydrolytic deamination of C to U depends on the glutamate residue at
position 58 (E58) for acid-base catalysis, and the histidine at residue 56, and
cysteines at positions 87 and 90 (H56, C87, and C90 respectively) for zinc
coordination to activate a water molecule. The C-terminus of the protein is
required for CSR while the N-terminus is required for SHM.
1.1.3 AID and Subcellular Localization
The gene encoding AID has five exons and is located in close proximity to
the APOBEC-1 gene on the same chromosome in both mice (chromosome 6)
and humans (chromosome 12). As described above, the catalytic domain or zinc
coordination motif of AID is conserved with other members of the APOBEC
family of proteins. Mutation of the glutamate residue at position 58 (E58) in the
catalytic domain of AID can result in a catalytically inactive mutant (see Figure 2).
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E58 is thought to participate in general acid-base catalysis and residues H56
(histidine), C87 and C90 (cysteine) coordinate with a Zn2+ along with an activated
water molecule to mediate nucleophilic attack of the carbon-4 of cytosine,
promoting deamination or loss of the amino group (see Figure 3) (16, 17). This
catalytic domain of AID is required for both in vivo SHM and CSR.
With a functional catalytic domain intact, mutational experiments of AID
revealed that the carboxy-terminal (C terminal) domain of the AID protein (198
amino acids, ~24 kDa) is necessary for CSR, while the amino‑terminal (N
terminal) domain is required for only SHM (18-20). The C and N terminal
domains also play a role in the subcellular localization of AID. Since AID acts on
genomic DNA of activated B cells, nuclear localization is required. However,
because of its mutagenic potential, AID is actually a nucleocytoplasmic shuttling
protein (21). A nuclear export signal NES is located in the last ~10 residues of
the C terminal domain (22-24) while a nuclear localization signal (NLS) was
identified encompassing most of the N terminal domain (see Figure 2) (22, 25).
Recent work has also demonstrated that subcellular compartmentalization of AID
also depends on active cytoplasmic retention which may afford overall genomic
protection from this DNA mutator enzyme (25).
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Figure 3: Proposed Mechanism of AID Catalyzed Deamination of Cytosine

Figure 3: Proposed Mechanism of AID Catalyzed Deamination of Cytosine.
The catalytic pocket of AID contains the glutamate residue at position 58 (Glu58)
which participates in general acid-base catalysis for the activation of a water
molecule. Cysteines at positions 87 and 90 (Cys87, Cys90) and histidine 56
(His56) coordinate a zinc along with the water molecule. The remaining hydroxyl
group serves as a nucleophile to attack the C4 position of a cytosine, yielding an
intermediate that eventually gives rise to uracil once an ammonia group leaves.
The proposed mechanism shown above for AID is based on homology with
cytidine deaminases and mutational studies (16, 17, 26). Figure created in
ChemBioDraw Ultra 14.0
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1.2 The Role of AID in the Adaptive Immune System
The immune system of vertebrates is composed of innate immunity and
adaptive immunity (27). Innate immunity is the immediate line of defense and is
nonspecific towards the antigen. Anatomical barriers such as mucosal and
epithelial surfaces, inflammation, and broad recognition of pathogen-associated
molecular patterns (PAMPs) by particular cells of the immune response system,
define this branch of innate immunity (28). However, innate immunity does not
offer long-term protection or ‘memory’ against previously encountered antigens
but plays a role in the activation of adaptive immunity. This second branch of the
immune system, also referred to as acquired immunity, is antigen-specific and
has the ability to confer immunological memory. AID plays a role in producing
antibodies required for an appropriate adaptive immune response.
1.2.1 The Structure and Function of Immunoglobulins
Antibodies, or immunoglobulins, are either expressed on the surface
membrane of B cells as B cell receptors (BCR) or are secreted by plasma cells, a
specific type of differentiated B cell (28). Immunoglobulins are glycoproteins with
a base unit of a homodimer of a heterodimer (27). The heterodimer is comprised
of a longer ‘heavy’ polypeptide chain and a shorter ‘light’ chain. Disulfide bonds
bridge the heavy chain and light chain of the heterodimer as well as the
homodimer (see Figure 4A). There are two antigen binding pockets, or variable
domains, in the base unit of antibodies (see Figure 4A). Mutations from SHM
produce antibodies with different primary sequences for their antigen sites, hence
‘variable domain,’ to confer high affinity against antigen (see Figure 4B, and
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Figure 5B). In contrast, CSR or lack thereof, determines the constant domain of
the immunoglobulin (see Figure 4C and Figure 6). The final antibody structure
can be secreted as a monomer, dimer, or even hexamer of this base unit
depending on the isotype (ie. IgM can form a pentamer with ten antigen binding
sites).
Figure 4: Structure of Immunoglobulins

‘BASE UNIT’ of Immunoglobulin

Figure 4: Structure of Immunoglobulins. (A) Immunoglobulins, or antibodies,
consist of a base unit of a homodimer of a heterodimer. The heterodimer consists
of the ‘heavy’ polypeptide chain and the shorter ‘light’ chain. Thus, the
homodimer has two heavy and two light chains as depicted. Disulfide bonds
bridge the heterodimer and the homodimer. There are two antigen binding
pockets, or variable domains, in the base unit of antibodies. (B) Somatic
hypermutation occurs when AID introduces mutations that alter the variable
regions of the Ig gene to produce higher affinity antibodies for specific antigen,
indicated here as a change in shape of the antigen binding pockets to fit the
antigen more appropriately. (C) Class switch recombination occurs when AID
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introduces double strand breaks that eventually lead to juxtaposition of a new
constant domain downstream of the variable region resulting in a gene that
codes for a new isotype. CSR is depicted here as a change in color of the
constant heavy chain from IgM (purple) to IgE (pink).
High affinity immunoglobulins not only neutralize foreign pathogens but
are also essential in activating several other immune responses to combat
infection. The different isotypes of antibodies (IgM, IgD, IgG, IgA, and IgE) are
coded by the different constant regions in the heavy chains of the Ig gene (Cµ,
Cδ, Cγ, Cα, and Cε respectively and see Figure 6). CSR is designed to yield the
immunoglobulin isotype that is best equipped to eradicate the specific pathogen
based on the nature of the antigen and the ability of the antibody to reach the
tissue site of the infection. For example, since IgM is secreted as a large
pentamer or hexamer, it cannot traverse into extravascular space. This makes it
unsuitable to neutralize antigens distributed in that tissue, in contrast to
monomeric IgG. In addition, antibodies are switched to the isotype best able to
eradicate the specific pathogen type. For example, IgE is suited for parasitic
infections (29) and IgA is effective against mucosal bacteria (30).
1.2.2 Antibody Affinity Maturation
The initial expansion of the antibody repertoire arises from the process of
V(D)J recombination which is both independent of available antigen and T-cells,
and does not require AID. This is a combinatorial process that occurs early in B
cell development to establish a variable region through rearrangements of the
variable (V), diversity (D) and joining (J) segments in the Ig gene (31, 32).
Further expansion and diversification of the antibody repertoire is achieved by
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SHM and CSR which are antigen-dependent processes that continue to alter the
Ig gene and as described above, absolutely require AID. All three processes are
essential for antibody maturation.
Figure 5: SHM of the Variable Region of the Immunoglobulin Gene

Figure 5: SHM of the Variable Region of the Immunoglobulin Gene. (A) A
truncated immunoglobulin gene (heavy chain) with a rearranged V(D)J region is
schematically depicted. The variable region, V(D)J, is depicted in blue. The
enhancer (Eµ), switch region (Sµ), and constant domain (Cµ) that codes for IgM
(purple) is downstream of the variable region. Thus, without class switching, the
default encoded Ig isotype is IgM. The Sε and Cε (pink) are the respective switch
region and constant domain for the IgE isotype, and Sα and Cα (orange) are the
switch and constant domains for the IgA isotype. The 3’ Regulatory Region
(3’RR, red) is composed of enhancers that promote efficient CSR (33) and SHM
(34). (B) Somatic hypermutation occurs when AID-dependent point mutations,
depicted as yellow bars, are introduced in the V(D)J region of the Ig gene. AID
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acts on single-stranded DNA during transcription and the V(D)J transcription start
site (TSS) is shown as a red arrow.
Figure 6: Class Switch Recombination

Figure 6: Class Switch Recombination. Elements of the Ig gene are depicted
similar to that in Figure 5. (A) Before CSR, the Ig gene codes for an IgM
transcript. Upstream of each constant domain is a switch region, S, that is
transcribed from an intronic promoter (red arrows) since AID requires
transcription. When class switching from IgM, the default coded constant region,
to another isotype, AID deaminates cytosines to uracils in Sµ and Sdownstream.
Sdownstream in this case is Sε. (B) Through the excision of uracil by UNG, nicking of
the AP site by APE, and error prone BER or MMR, double strand breaks (DSBs,
green arrows) are introduced. (C) Upon resolution of the DSBs by nonhomologous end joining or alternative end-joining (not shown), an Sµ and Sε
synapsis brings the Cε region downstream of the V(D)J which allows for the
coding of IgE. The intervening DNA region which contains the Cµ domain is
ligated into a ‘switch circle’ and deleted.
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Post V(D)J recombination, AID introduces point mutations within the
rearranged V(D)J segments of the Ig gene in B cells during SHM (see Figure 5B)
(2-4, 35). Those B lymphocytes which attain somatic mutations that improve
antibody affinity for the antigen are positively selected for while those B cells that
acquire mutations that reduce affinity of the antibody for the antigen are removed
from the B cell population via programmed cell death. This clonal selection allows
for the evolution of progressively higher affinity antibodies with each continuous
and iterative step of SHM (see Figure 7 Clonal selection) (36, 37).
Figure 7: Clonal Selection of High-Affinity Antibodies

4

1
2
3

Figure 7: Clonal Selection of High-Affinity Antibodies. Naïve B cells (clones
1,2, and 3) having undergone V(D)J recombination express different surface
antibodies (Ab). Only the Ab on the surface of clone 3 has some affinity to a
specific antigen (Ag, blue rectangle). Through receptor binding, T cells recognize
this Ab-Ag complex and mediate clonal expansion by promoting proliferation of
clone 3. SHM and CSR help produce high affinity Abs and the correct isotype
needed for the specific antigen. Clones that acquire mutations during iterative
rounds of SHM and Ag exposure (circular arrow) that result in reduced or poor
affinity Abs undergo programmed cell death, while those that acquire beneficial
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mutations expand. ‘Clone 4’ has class switched and has a high affinity Ab to the
specific Ag. Figure created in ChemBioDraw Ultra 14.0
CSR is a programmed DNA recombination process that yields the most
effective antibody isotype needed during each immune response (35, 38). During
CSR, the rearranged variable region is joined with one of several different
downstream constant regions (ie Cα, Cγ, Cε) that each confer a specialized
optimal effector function. Switch (S) regions which contain short repetitive
sequences are located upstream of the constant regions in the Ig genes (see
Figure 6). Following AID-dependent introduction of double-strand breaks in Sµ
and a second downstream S region, the intervening sequence is circularized and
deleted while the two different S regions are joined together (39). This juxtaposes
the V(D)J exon to a downstream constant region exon that results in isotype
switching from IgM to IgA, IgG, or IgE (see Figure 6 for a schematic of IgM to IgE
isotype switching).
In addition to SHM and CSR, some vertebrates evolved a third AIDdependent mechanism of antibody affinity maturation known as gene conversion
(GCV) (40, 41). In species, such as chicken, pigs, and rabbits, GCV is the
dominant method of V segment diversification (42, 43). This process does not
take place in the biological systems studied in this work, mice and human B cells,
and thus will not be discussed in detail here.
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1.2.3 The Mechanism of Somatic Hypermutation
1.2.3a Mutational Characteristics of the Immunoglobulin Gene and SHM
During SHM, AID introduces mutations in the variable segment of the
heavy chain of the Ig gene in activated B cells, with the highest occurrence of
mutations found in the exons of the V(D)J segment. In addition mutations are
acquired in the introns of the J regions as well. However, AID avoids mutating the
C domain genes. The promoter regulatory regions and an enhancer element
located in the intron also evade AID induced mutations (see Figure 8) (44, 45).
Figure 8: Intensity and Boundaries of SHM in the Variable Region

Features of Somatic Hypermutation
of the Variable Region

Figure 8: Intensity and Boundaries of SHM in the Variable Region. The level
of the mutation frequency (y axis) of the immunoglobulin heavy chain is
schematically (not to scale) depicted along the regions of the Ig gene (x axis).
The transcription start site (red arrow) begins at the promoter (P). Somatic
hypermutations are found approximately 100 to 200 base pairs downstream from
the TSS(46) with the highest accumulation of mutations found within the V(D)J
region. The mutations accumulate up to approximately 1500 base pairs
downstream of the TSS (47). The enhancer and constant domain (Eµ and Cµ,
respectively) do not undergo SHM. Adapted from figures in references (46, 48).
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SHM may occur in switch regions as well but is not shown or discussed here
(48).
Mutations in SHM are predominantly found in the form of single base
changes, or ‘point mutations,’ and accumulate approximately 100 to 200 base
pairs (bps) from the transcription start site (TSS) with the mutation spectrum
extending up to approximately 2.0 kb downstream of the TSS (44-46, 49, 50).
Furthermore, in SHM, most of the point mutations are transitions (e.g. pyrimidine
mutated to a pyrimidine, purine mutated to a purine) rather than transversions
(e.g. pyrimidine mutated to a purine and vice versa). Since AID has sequence
selectivity, it is not surprising that many mutations in the V(D)J segment are
targeted to the WRC hotspot motif (15, 47, 51).
The frequency of SHM mutations is approximately 106 fold higher than that
for background genomic mutations- the V(D)J segment can accrue roughly 10-3
mutations per base pair per generation (16). High SHM mutation frequency in the
variable region also correlates with high transcription levels (52). SHM requires
transcription, but transcription alone is not sufficient to ensure AID activity.
Transcription is thought to provide the single-stranded DNA substrate needed by
AID, in the form of a ‘transcription bubble’ (53). SHM is not strand biased, with a
similar mutation frequency seen in both the template strand (TS) and the
nontemplate strand (NTS) (54).
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1.2.3b Error-Free Base Excision Repair of Uracils
Simple direct replication across from an AID-introduced uracil will
eventually produce a G/C transition mutation after a second round of replication
(see Figure 9 Upper Right) (10). The replicating DNA polymerase will insert an A
across from a template U, effectively treating the DNA lesion as a template T.
The mutations of SHM are not just C to T transition mutations and not restricted
to G/C bases but occur just as efficiently at A/T base pairs in SHM. Thus, simple
replication cannot be the only mechanism in activated B cells that leads to a
hypermutated Ig gene.
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Figure 9: Model of Somatic Hypermutation of the Variable Region

Figure 9: Model of Somatic Hypermutation of the Variable Region. AID
deaminates C to U in the V(D)J region of the Ig gene of B cells. The resulting
U•G mispair can be processed in several ways. (Upper Right) Replication past a
U will result in the insertion of an A, eventually resulting in a C to T transition
mutation in one daughter cell after a second round of replication. (Lower Right)
Uracil DNA-glycosylase (UNG) can excise the uracil resulting in an AP site that
can be bypassed by error-prone translesion synthesis polymerases (TLS). These
polymerases may insert any of the four nucleotides resulting in C to N mutations.
(Middle) Canonical base excision repair (BER) depends on the excision of U by
UNG, nicking of the AP site by APE, and polβ and ligase to correctly restore the
C:G base pair. (Left) Mismatch repair (MMR) proteins, specifically MSH2/6,
recognize the U•G mispair. Exonuclease 1 helps to create a gap around the
initial U lesion and TLS polymerases are then recruited and insert any of the four
nucleotides throughout the excised gap. This results in transition and
transversion mutations at A:T and G:C base pairs.
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The evolution of antibody affinity maturation which promotes mutations of
the Ig gene requires more than just AID, a targeted DNA mutator. It also requires
evolution of downstream pathways to ensure the AID generated uracils are not
simply excised and repaired by the several highly conserved DNA damage repair
systems in place to protect genomic instability. To circumvent error-free repair of
the uracils, many enzymes involved in canonical genomic uracil repair pathways
have been hijacked to play counter-intuitive roles in activated B cells to ensure Ig
gene mutations.
Since uracil is introduced into genomes by pathways other than the
enzymatic deamination of cytosines by members of the AID/APOBEC family of
proteins, highly conserved DNA repair pathways have evolved to remove and
excise genomic uracils, restoring sequence context. The misincorporation of
uracil during replication, and the non-enzymatic spontaneous deamination of
cytosine to uracil, both result in uracilated DNA. Uracil generated through
misincorporation of a dUMP occurs when the replicating polymerase uses dUTP
as a substrate rather than dTTP (see Figure 10 for details). This results in U:A
base pairs that are not directly mutagenic. In contrast, spontaneous deamination
of a cytosine in a C:G base pair results in a U•G mispair that can lead to a C to T
mutation if unrepaired and replicated past, similar to consequences from AID
deaminated cytosines (see Figure 11).
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Figure 10: Pathways for Uracil Incorporation in DNA

Figure 10: Pathways for Uracil Incorporation in DNA. (A) Uracil can be
misincorporated into DNA during replication. Generally, this is avoided by actively
keeping the dUTP pool low due to dUTPase (deoxyuridine 5’ triphosphate
nucleotide-hydrolase). As depicted above, dUTPase hydrolyzes dUTP to dUMP
(and pyrophosphate, not shown). Thymidylate synthase reductively methylates
dUMP during de novo synthesis of dTMP. dTMP is then converted to dTTP which
is a substrate for DNA polymerase (DNA pol) during replication. dUMP is
produced from the deamination of dCMP by DCD (deoxycytidylate deaminase).
In addition, RNR (ribonucleotide diphosphate reductase) converts UMP to dUDP
which is then phosphorylated to dUTP. DNA pol is able to use available dUTP as
a substrate and inserts uracil across from a template A during replication. (B)
Uracil can also occur in DNA through hydrolytic non-enzymatic spontaneous
deamination of cytosine as depicted. Cytosines can also be deaminated
chemically, for example by bisulfite(55) and nitrous anhydride(56) (not shown).
Figure created in ChemBioDraw Ultra 14.0
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Figure 11: Mutational Consequences of Uracil in DNA

Figure 11: Mutational Consequences of Uracil in DNA. (A) The
misincorporation of dUMP instead of dTMP by DNA polymerase (DNA pol) yields
a U:A base pair. When this undergoes replication (Replication 1) a normal T:A
base pair is generated and an A is inserted across from the U in the top strand. A
second replication event (Replication 2) also results in normal T:A base pairs and
further dilutes the non-mutagenic U:A base pair until it can be excised and
repaired. (B) Deamination of cytosine to uracil, whether spontaneous or
enzymatic is mutagenic. This results in a U•G mispair. Replication past this
(Replication 1) results in a U:A base pair as well as a C:G base pair. Another
replication event (Replication 2) fixes a C to T mutation (green star).
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Figure 12: Uracil DNA-Glycosylase

2’deoxyuracil

Abasic Site

Free uracil

UNG

Figure 12: Uracil DNA-Glycosylase. Uracil DNA-Glycosylase (UDG) recognizes
uracil in single-stranded DNA, or in U:A and U•G pairs. Through hydrolysis of the
N-glycosidic bond, UDG excises uracil from DNA. This results in the formation of
an AP site, or abasic site, and the release of free uracil and is the first step in
base excision repair. Figure created in ChemBioDraw Ultra 14.0
The faithful process of base excision repair (BER) (see Middle, Figure 9)
maintains the integrity of DNA by removing and repairing various lesions and
adducts through a multiple-step pathway. Canonical BER is initiated by the
excision of the DNA lesion by DNA glycosylases capable of recognizing and
excising DNA adducts through hydrolysis of the N-glycosidic bond. Thus, uracils
are removed by uracil-DNA glycosylases (see Figure 12). There are four types of
uracil-DNA glycosylases (UDG or UNG) in mammalian systems which include
UNG, single-strand specific monofunctional uracil-DNA glycosylase 1 (SMUG1),
thymine-DNA glycosylase (TDG), and methyl-CpG binding domain protein 4
(MBD4) (57, 58). The mammalian UNG gene encodes the two existing isoforms
of UNG, mitochondrial UNG1 and nuclear UNG2 (59). The evolution of several
redundant glycosylases with the ability to remove genomic uracil highlights the
selective pressure against uracils accumulating in the genome. TABLE 1 lists all
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the different DNA lesions in the context they are recognized in by the individual
glycosylases capable of removing uracils. UNG2 is the major glycosylase
responsible for removal and initiating repair of genomic uracil with SMUG1
thought to be the primary back-up enzyme (57, 60).
TABLE 1: Substrates of the Human Uracil DNA Glycosylases

Glycosylases
UNG1/UNG2

SMUG1

Substrates

References

U in ssDNA
U:A
U•G

(61)

U in ssDNA
U:A
U•G
5hmU in ssDNA
5hmU:A
5FU:A

(62, 63)

TDG

T•G
U•G
εC:G

MBD4

T•G
U•G

(64)

(65)

TABLE 1: Human Uracil DNA Glycosylases are indicated with
substrates shown in bold.
Upon recognition of uracil, UNG2 cleaves the N-glycosidic bond to release
free uracil base generating an abasic site (AP) in the DNA. AP endonuclease
(APE) then nicks the AP site. The deoxyribophosphodiesterase (dRPase) activity
of DNA polymerase β (Polβ) cleaves the 3' end of the nicked abasic site and
releases deoxyribose-5-phosphate (dRP). Polβ then inserts the correct base
according to the template- a C to restore the C:G base pair if the uracil resulted
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from deamination or a T to restore the T:A base pair if the uracil was
misincorporated during replication. DNA ligase then seals the nick to complete
what is termed ‘short patch’ BER, the removal of only the uracil base and the
insertion of one correct nucleotide (see Figure 9 Middle). ‘Long-patch’ BER
involves the replicative machinery and polymerases, flap endonuclease-1
(FEN1), and removal and repair of a gap of ~ 2 to 10 nucleotides to repair the
uracil lesion (66). Contradictory to their primary roles, during SHM of activated B
cell, UNG2 and APE function to promote mutations.
1.2.3c Error-Prone Resolution and UNG2 in SHM
Similar to patients deficient in functional AID protein with HIGM2
syndrome, mutations in the human UNG2 gene result in a similar disorder termed
HIGM5 where their antibodies are also compromised in SHM and CSR (67, 68).
The introduction of mutations during SHM is dependent on UNG2 for removal of
the AID induced uracil and generation of an AP site (69, 70). UNG2 is primary for
shaping the mutational spectrum of SHM at G/C base pairs. While mutations at
A/T base pairs occur during SHM, they seem to be predominantly dependent on
a different repair pathway (see section 1.2.3d).
UNG2 excises uracils introduced in the variable region of the Ig gene by
AID similar to the first step of error-free BER. Since the resulting AP sites have
no instructive base, they cannot be bypassed by replicative polymerases and
thus, error-prone translesion synthesis polymerases (TLS) are recruited. These
polymerases are capable of bypassing the AP site (71) since the promiscuous
nature and more permissive binding site of the TLS polymerases allows for the
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insertion of any of the four nucleotides across the AP site. This results in G/C
transitions and transversions during SHM (72) (see Figure 9).
1.2.3d Mismatch Repair and A/T Mutations in SHM
Replicative polymerases are equipped with proofreading capabilities to
correct mismatch errors that may occur during insertion of an incorrect dNMP.
However, if a replication error escapes detection as well as correction by the
replicative polymerase, a highly conserved repair pathway is available for
recognition and repair of the mismatched base pair to avoid mutations. This
pathway termed mismatch repair (MMR), is a multi-step process which depends
on several proteins for the recognition, removal, and repair of the DNA as well as
complex interactions with the DNA replication machinery (73, 74). Not unlike the
BER pathway, some MMR proteins have also been exploited to actually promote
mutations in the Ig gene of activated B cells. Only MMR proteins relevant to
antibody affinity maturation will be discussed.
MMR proteins were initially discovered to affect SHM in studies of mice
deficient in MutSα, a complex consisting of the factors MSH2 and MSH6 that are
required for recognition of non- Watson-Crick base pairs. The majority of
hypermutations at A/T base pairs in the activated B cells were reduced by ~85%
(75, 76). MutSα recognizes the AID generated U•G base pair in the variable
region and an endonuclease is thought to make an incision 5’ to the mismatch.
This allows Exonuclease 1 (Exo-1) to degrade the DNA and generate a gap
around the initial uracil lesion. Exonuclease 1 is responsible for generating a gap
in the strand with the misincorporated base during normal MMR, and performs a
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similar role in promoting A/T base pair mutations during SHM (77). Recent
evidence suggests that in germinal center B cells, nicking of AP sites by APE2
may provide an accessible end for Exo-1 (78, 79). A large gap is required to
avoid confining mutations to just the initial AID lesion and allows for more
mutations around the original deaminated cytosine. Finally, as in UNG2
dependent mutations in SHM, it is TLS polymerases that are recruited and fill in
this gap in an error-prone manner, creating transitions and transversions at A/T
base pairs (see Figure 9).
The majority of A/T mutations in SHM are dependent on MMR recognition
factors, but ~15% can still be found in the Ig genes of activated B cells of MutSα
deficient mice. However, complete ablation of A/T mutations occurs in mice that
are deficient in both UNG2 and MSH2 (69, 80). Similar results are seen in mice
deficient in UNG2 and MSH6 (81). This supports a secondary role for UNG2 in
generating a minority of the A/T transitions and transversions around the original
uracil lesion and it is proposed that error-prone long-patch BER may be involved.
1.2.4 The Mechanism of Class Switch Recombination
AID is required to initiate CSR, but unlike SHM, the uracils generated are
not processed to promote mutations. Instead, AID induced uracils during CSR
are converted to double-strand breaks (DSBs), and then resolved to adjoin the
variable segment of the Ig gene to a new constant domain, with the intervening
sequence circularized and degraded. Similar to SHM, however, is that this
deletion-recombination event depends on BER and MMR proteins to promote
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genomic instability, contrary to their ubiquitous primary roles in protecting the
genome.
1.2.4a Switch Regions and CSR
Downstream of the V(D)J segment of the Ig gene are the constant
domains which code for the effector functions of the antibody (see Figure 5A and
6). Directly upstream of each constant domain, with the exception of Cδ, is a
switch region (S). Each S region has an upstream ‘intronic’ or ‘intervening’ (I)
exon with its own promoter. Since AID requires transcription, the I exon and its
associated promoter ensure transcription through the S region and thus allow for
targeting of the S region by AID (82). The induction of transcription of different I
exon promoters are cytokine or cytokine cocktail specific to stimulate class
switching to different constant domains, and thus effector functions, as needed.
For example, stimulation by interleukin-4 (IL-4) can induce germline transcription
of the Iε, ensuring access of AID to the S region directly upstream of Cε, and thus
allow for switching from the default IgM to IgE (83, 84). This transcription
produces a germline transcript (GLT) which is considered a ‘sterile’ transcript, as
it lacks an open reading frame and is not translated (82). GLTs are essential to
CSR (85).
As targets of AID, it is not surprising that S regions contain frequent AID
hotspot motifs (ie WRC). For example, the core of the switch region contains 5ʹAGCT-3ʹ repeats and this motif is highly enriched in the S regions compared to
the rest of the genome (86). Furthermore 5ʹ-AGCT-3ʹ sequences ensure a WRC
AID deamination motif in both DNA strands (87). S regions are also characteristic
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of containing a NTS enriched with G nucleotides. These clusters of G nucleotides
promote the formation of R-loops where the transcribed mRNA strand hybridizes
with the TS of DNA. This causes displacement of the NTS and allows a single
stranded DNA loop of potentially hundreds of nucleotides to form (88). Thus,
WRC motifs, R-loops, and GLT ensure S regions are a welcoming DNA substrate
for AID.
1.2.4b AID Promotion of Double-Strand Breaks
During CSR, AID introduces uracils in the Sµ region as well as the
downstream S region (Sdownstream) that has been upregulated for transcription
upon response to stimulation with specific cytokines. In class switching to IgE, for
example, AID introduces uracils in the downstream Sε region, but effective CSR
depends on a complex of proteins forming at the S regions. Particularly, AID is
recruited to the 5ʹ-AGCT‑3ʹ enriched S regions by 14-3-3 adaptor proteins to
allow for deamination of cytosines. The TLS polymerase Rev1 recruits UNG2 to
excise AID generated uracils. Evidence supports Rev1 plays only a scaffolding
role, bringing UNG2 to the S regions, since CSR is independent of Rev1
enzymatic activity (89). 14-3-3 adaptor proteins have also been shown to directly
interact with and stabilize UNG2 at the S region (90). The AP sites, resulting from
UNG2-excision of uracils, are nicked by APE1 and form SSBs (91). In addition to
APE1, lyase activity of MRE11–RAD50 may also process and cleave AP sites
(92).
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Since AID activity is not strand biased, and WRC motifs occur in close
proximity on both strands, AP sites and therefore nicks are generated in both the
TS and NTS promoting direct DSB formation in the S regions. MMR proteins,
including MutSα and Exo-1, also help to produce DSBs in the flanking regions.
The AID dependent DSBs created in both Sµ and Sdownstream are resolved by
classical non-homologous end joining (c-NHEJ) or alternative-end joining (A-EJ)
(84). Finally the intervening sequence is excised and circularized. This ‘switch
circle’ is eventually degraded. Thus, the V(D)J segment is juxtaposed to the SµSdownstream junction and allows for class switching to the new constant domain
(see Figure 6 for a schematic of IgM to IgE class switching).
1.3 The Role of AID in Lymphomagenesis
AID is a DNA mutator enzyme and its ectopic expression may play a role
in the transformation of tissue from hepatocytic, gastric, mammary, and oral
epithelial origin (93-97). Despite the tight regulation of subcellular localization, Ig
gene targeting, and restricted B cell spatiotemporal expression, it is not
unexpected that AID is proposed to have a role in the development of germinal
center (GC) B cell lymphomas. The GC microenvironment promotes AID
dependent mutations and DSBs in the Ig gene. However, aberrant SHM or CSR
at non-Ig genes can be deleterious to the activated B cells leading to cancer.
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1.3.1 The Germinal Center Reaction
AID is primarily targeted to the Ig genes of B cells and is found highly
expressed in B cells exposed to antigen and undergoing antibody maturation (2,
3). The upregulation of AID and antibody maturation occurs in the germinal
centers (GC) which are temporary microenvironment structures essential to the
immune response that develop upon exposure to antigen. They are located in
secondary lymphoid tissues such as the spleen and lymph nodes (84, 98, 99).
GCs foster an environment of collaboration between specialized immune cells
with the primary function of generating B cells with high-affinity antibodies. Thus
the “germinal center reaction” (GC-reaction) requires upregulation of AID and the
processes of SHM and CSR (98).
Figure 13: The Germinal Center Reaction

Figure 13: The Germinal Center Reaction. Post V(D)J recombination,
precursor B cells develop into naïve B cells that have not been exposed to
antigen. After exposure to antigen, germinal centers are formed in secondary
lymphoid structures such as the spleen and lymph nodes, and have two
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histologically identifiable regions, the ‘dark zone’ (DZ) and the ‘light zone’ (LZ).
AID-dependent SHM and CSR occur in the GC-reaction. This leads to mutations
and class switching in order to form high affinity antibody producing B cells.
These will differentiate into plasma cells and memory B cells. However, not all
mutations accumulated during the GC-reaction are beneficial and thus, these B
cells undergo apoptosis as depicted above. Some AID-dependent mutations or
translocations acquired during the GC-reaction may be deleterious ( ) and
promote lymphomagenesis.
Prior to antigen exposure, the only diversification event that occurs in
antibodies is V(D)J recombination in B cells early in development (pro- and pre-B
cells). This takes place in the primary lymphoid tissue of the bone marrow. V(D)J
recombination alone does not result in high affinity antibodies. Before GC
development, secondary lymphoid organs are found to contain primary follicles
which consist of predominantly naïve B cells that have not been subjected to
interaction with antigen. Post antigen-exposure, however, GCs begin to form
within the primary follicles and thus, force the naïve B cell population to the
periphery of the follicle and form the region termed the B cell mantle (36). Early
GCs are separated into ‘dark zones’ (DZ) and ‘light zones’ (LZ) which are
histologically visible divisions (see Figure 13 for a schematic overview) (99, 100).
The DZ primarily contains B cells exposed to antigen, ‘activated’ B cells, that
express high levels of AID (or centroblasts) and undergo SHM and CSR (36,
101) while the LZ has antigen-selected GC B cells (or centrocytes) which also
express AID and can undergo CSR. LZs also contain specialized cells which
participate in the presentation of antigens to B cells and their development.
These include follicular dendritic cells (FDCs) CD4+ and CD8+ T cells and
tingible-body macrophages (TMϕs). TMϕs are a specific type of macrophage that
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phagocytose B cells undergoing apoptosis during clonal selection in the GC
reaction (102, 103).
Once GC B cells have acquired antibodies with high affinity against the
antigen, they can exit the GC and differentiate into antibody secreting cells
known as plasma cells to help eradicate the current infection. Other GC exiting B
cells will differentiate into memory B cells to provide for a more rapid and longterm immunological response against a second future exposure to the antigen.
The GC reaction is essential to the adaptive immune system. However, this
process of promoting AID-induced mutations and strand breaks in DNA for
antibody affinity maturation bears considerable risks in the form of inadvertent
oncogenic mutations and translocations.
1.3.2 Features of B Cell Lymphomas
The translocation of the Ig gene with a proto-oncogene is characteristic of
many types of B-cell lymphomas. This deleterious chromosomal rearrangement
may result in the constitutive expression of the oncogene as it comes under the
transcription regulation of the Ig gene due to its juxtaposition (104-106). Studies
have demonstrated that AID is essential for the formation of the c-Myc-IgH
translocation found in specific B cell lymphomas (107, 108). Aberrant CSR is
thought to be the culprit, where DSBs in the Ig are incorrectly adjoined to DSBs
in the c-Myc oncogene from mis-targeting of AID, resulting in a reciprocal
translocation. The transformative potential of Ig-oncogene translocations in B cell
lymphomas has long been ascertained, pre-dating the discovery of AID (109).
Aberrant SHM has also been implicated in oncogenic translocations with the Ig
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gene but more importantly in promoting detrimental hypermutations. These
mutations in non Ig genes, such as those that regulate B cell development,
regulation, and survival, may promote B cell lymphomagenesis (110-112).
Studies in transgenic mouse models have elucidated the requirement of AID for
the development of GC-derived B cell lymphomas, but not lymphomas that
develop from pre-GC B cells (113). The majority of human B cell lymphomas are
thought to originate from a transformation event that occurred in the GC
microenvironment. This is hardly surprising given the mutagenic potential of AID
in GC B cells where DNA damage in the form of mutations and DSBs is
encouraged, and cells are highly and rapidly proliferating. TABLE 2 summarizes
the human B cell lymphomas relevant to this work.
1.3.2a Burkitt Lymphoma
AID is required for the t(8;14) translocation which involves the c-Myc gene
on chromosome 8 and the IgH locus on chromosome 14 (see Figure 14) (107,
108). Myc is a transcription factor thought to regulate approximately 15% of
genes in B cells (114). These include genes responsible for cell cycle regulation,
apoptosis, and proliferation. Thus, deregulation and constitutive overexpression
of Myc can lead to compromised cell cycle control, reduction in necessary
programmed apoptosis, and uncontrolled rapid proliferation promoting genome
instability and tumorigenesis (115). The t(8;14) translocation is a hallmark of
human Burkitt Lymphoma (BL). BL is categorized into two subtypes, the endemic
form which is predominantly found in young children in tropical Africa and the
sporadic form found throughout the world at a much lower prevalence. Endemic
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BL is associated with malaria and Epstein-Barr virus (EBV) while the majority of
the sporadic form is not (116, 117).
The c-MYC-IgH translocation in sporadic BL occurs due to breakpoints in
the S region of the IgH gene, and thus arises due to aberrant CSR (106, 118).
However, due to breakpoint locations near the V segment of the Ig gene in
endemic BL, translocations found in this subtype are thought to arise from
aberrant SHM (119).Characteristic of BL is the expression of surface markers
normally expressed on GC B cells. In addition, hypermutated V regions are
detected which indicates the cells have previously undergone SHM. This
supports the notion that BL originates from GC B cells that have acquired
transformation during the GC reaction (120). Studies have revealed that BL cells
are hypermutated at non-Ig genes, are constitutively undergoing acquisition of
hypermutations, and have undergone antigen selection (121, 122).
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Figure 14: Schematic of c-MYC-Ig Translocation

Figure 14: Schematic of c-Myc-Ig Translocation. The Myc gene (red) is
located on human chromosome 8 (blue) and the immunoglobulin gene (Ig,
yellow) is located on chromosome 14 (green). Upon deleterious AID-dependent
double strand breaks (DSBs) during the GC-reaction and faulty resolution, a
reciprocal Myc-Ig translocation results where Myc is juxtaposed to Ig (t(8;14) or
Myc-Ig in the figure). This translocation is a hallmark of Burkitt Lymphoma and
many lymphomas are found to have translocations between Ig and protooncogenes. Figure created in ChemBioDraw Ultra 14.0
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TABLE 2: Human B Cell Lymphomas
Lymphom
a

B Cell Type
Origin

(Percent of
Western
Lymphomas
)

Diffuse
Large B
Cell
(DLBCL)
(30-40%)

Follicular
Lymphoma
(FL)

GC B cell
or
Post-GC B
cell
(plasma)

GC B cell

(20%)

Burkitt
Lymphoma
(BL)

GC B cell

Association
with AID?

Constitutive
AID expression;
Aberrant CSR and
SHM

Aberrant SHM and
V(D)J recombination;
many FLs
constitutively
express AID

Constitutive AID
expression,
constitutive GC
phenotype and SHM

(2%)

B- Cell
Chronic
Lymphocyt
ic
Leukemia
(CLL)
(7%)

Pre-GC
B cell,
GC- B cell,
or
Post-GC
B cell
(ie. naïve,
GC, or
memory
B cells)

Heterogeneity in AID
expression- AID is
expressed at higher
levels in more
aggressive forms of
CLL with an
unmutated IgH-V
region; aberrant
SHM and constitutive
aberrant CSR

Translocations
& Chromosomal
Aberrations

MYC-IgH, IgKMYC, MYC-IgL,
Bcl-2-IgH, Bcl-6MYC, Bcl-2-IgH;

References

(106, 123126)

ongoing SHM in
many protooncogenes
Bcl-2-IgH,
constitutive SHM
of the IgH-V
region & protooncognes in
many patients

MYC-IgH
or
MYC-IgL

(127, 128)

(129-132)

Mutations
in TP53 and RB2

Trisomy 12;
mutations in
TP53/ATM/
NOTCH1/SF3-1;
deletions in
17p,13q,11q

(124, 132135)
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TABLE 2: Human B Cell Lymphomas (continued)
Lymphoma
(Percent of
Western
Lymphomas)

Marginal
Zone
Lymphoma
(MZL)

B Cell Type
Origin

Marginal
zone
B cell

Association
with AID?

No AID expression

(10%)

Multiple
Myeloma
(10%)

References

No characteristic
translocations

(124)

Deletion in 7q

(2%)

Classical
Hodgkin’s
Lymphoma

Translocations
& Chromosomal
Aberrations

Defective
GC
B cells,
T cells?

AID generally is not
expressed

DO NOT
retain GC
like traits

Post-GC
B cell
(plasma)

AID generally is not
expressed
Aberrant CSR
thought to occur
during transformation
event

No characteristic
translocations
Mutations in
several tumor
suppressor genes

MMSET-IgH
FGFR3-IgH
CCND3-IgH
CCND31-IgH
MAF-B-IgH

(124, 136,
137)

(138-140)

TABLE 2: Cell type origin, association with AID, and frequent chromosomal
aberrations for relevant human B cell lymphomas are indicated.
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1.3.2b Diffuse-Large B Cell Lymphoma
Diffuse-large B cell lymphoma (DLBCL) is the most prevalent type of nonHodgkin’s Lymphoma, accounting for approximately 30-40% of lymphoma cases
(141). DLBCL is classified into subgroups based on the phenotype of the
lymphoma, expression profiles, and the transformation pathways thought to give
rise to the cancer (142). The germinal center B cell-like (GCB) DLBCL has a
gene expression profile similar to normal GC B cells and also expresses high
levels of Bcl-6 which is generally found in centroblasts undergoing the GC
reaction (143). The activated B cell-like (ABC) DLBCL is thought to arise from
GC B cells differentiating into plasma B cells due to the down regulation of Bcl-6
expression in these lymphomas and the upregulation of several plasma cell
characteristic genes including XBP-1 (142, 144).
Like with BL, DLBCLs also have characteristic translocations but these
may involve the heavy (IgH) or light Ig chains (IgL or IgK). For example, the cMYC-IgH [t(8;14)], IgK-MYC [t(2;8)], and MYC-IgL [t(8;22)] translocations are
diagnostic chromosomal abnormalities in DLBCL patients (145). Translocations
involving IgH and different oncogenes also are characteristic of DLBCLs,
including Bcl-6-IgH [t(3;14)] and Bcl-2-IgH [t(18;14)]. Bcl-6 can also be found to
have other non-Ig gene partners in DLBCL translocations including Myc as in the
[t(8;30)] (126, 146). Translocations in both ABC-DLBCL and GCB-DLBCL are
proposed to occur due to illegitimate CSR (147). DLBCL is also known to
continually undergo aberrant SHM and acquire hypermutations in many non-Ig
genes throughout the genome due to overexpression of AID (148).
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1.3.2c Follicular Lymphoma
Follicular lymphomas are also thought to arise from B cells that have
undergone extensive SHM of the V region during the GC reaction, and account
for ~20% of diagnosed lymphomas (124, 149). Classification of FL is divided into
four grades based on the type of predominant GC malignant B cells that populate
the lymphoma. Grade 1 (G1-FL) consists of a majority of cancerous centrocytes,
G2-FL has both centrocytes and centroblasts, G3A-FL has a minor population of
centrocytes with a majority of centroblasts, and G3B-FL consist of only malignant
centroblasts (149). The majority of FLs carry a Bcl-2-IgH translocation, t(14;18),
which results in the overexpression of Bcl-2 that promotes continued cell survival
and blocks apoptosis (150, 151).
AID continues to be overexpressed in FLs of all grade types and is
implicated in introducing hypermutations in several proto-oncogenes such as cMyc, Pax-5, and Bcl-6 (128, 129). Recent sequencing studies of FL patient
samples have revealed that AID and aberrant SHM play a role in the evolution
and multiple recurrence of FL. AID continues to introduce mutations in Ig and
non-Ig genes shaping both genetic and epigenetic co-evolution of the cancer
(128, 152).
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1.3.2d Chronic Lymphocytic Leukemia
B-cell chronic lymphocytic leukemia (CLL) is the most prevalent form of
leukemia but is an extremely heterogeneous cancer which results in variable
clinical development (153). CLL falls into two essential prognostic groups that
consist of either having an unmutated IgH V region or a V region that has
undergone SHM. Patients with a mutated V(D)J segment have a better prognosis
with a survival median three fold higher than CLL patients with leukemia that did
not undergo SHM (154, 155). The B cell type that CLL arises from is debated.
Pre-GC naïve B cells, post-GC memory B cells, and GC- B cells have all been
suggested as the origin (124, 156). AID expression in CLL is also quite variable
ranging from low AID to extremely high AID expression, if expressed at all (156).
CLL patients can acquire mutations in DNA damage response pathways
including ATM, as well as tumor suppressor genes such as TP53 (132, 157).
However IgH translocations are not typically found in CLL.
1.3.2e Non-GC Derived B Cell Lymphomas
The majority of B cell lymphomas do arise from B cells undergoing the GC
reaction, however, several types of B cell lymphomas thought to originate from
pre- or post-GC B cells exist. From these two groups, however, more arise from
post-GC, having at least experienced the GC reaction before transformation,
than pre-GC B cells. For example, primary effusion lymphoma, multiple
myeloma, lymphoplasmacytic lymphoma, and hairy-cell leukemia arise from
plasma B cells or memory B cells (124).
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There are also some lymphomas whose origins are still yet not entirely
understood. Marginal zone lymphoma (MZL) is thought to arise from either preGC or post-GC B cells. There are two groups of MZL characterized by the site of
infiltration. Nodal-MZL predominantly presents in the lymph nodes while splenicMZL infiltrates the spleen and bone marrow. MZL does not carry characteristic
translocations but approximately 40% of MZLs have chromosomal deletions
around 7q22-36 (158). Similarly, the origin of classical Hodgkin’s lymphoma
(cHL) has also been debated, but most likely arises from defective GC B cells
(124). Hodgkin and Reed-Sternberg cells (HRS) are the cancerous cells in cHL.
These cells do not retain GC B cell expression profiles or phenotypes and a
minority of cases are thought to have a T cell origin (159). However nonbeneficial and deleterious mutations in the Ig genes of some cHL patients
suggest the lymphoma may have derived from the transformation of cells
destined to undergo apoptosis during the GC reaction (160). cHL cells have
mutations in several tumor suppressor genes and can also be associated with
EBV infection, but do not have IgH translocations.
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1.4 Scope and Significance
An overwhelming majority of human B lymphocyte malignancies derive
from cells that have undergone the GC- reaction and are associated with the
expression of the mutator enzyme AID. Thus, there is a critical need to elucidate
the global damage AID inflicts on the genome of normal and transformed cells.
Studying AID in the context of cancer is important to our understanding of how
mutations and translocations that promote B-cell lymphomas may arise. This is a
particularly interesting source of DNA damage because AID’s normal role in
adaptive immunity requires the deliberate introduction of uracils in the genome
but its mistargeting, ectopic expression, and aberrant behavior can promote
genomic instability. Furthermore, unlike most sources of DNA damage that
promote transformation, for example UV light and ionizing radiation, AID is an
endogenous enzymatic source of mutations. Recently, other members of the
APOBEC family have also been implicated in several other non-B cell cancers
that carry AID/APOBEC mutation “signatures” determined through base
substitution sequence analysis of the cancer genomes (161, 162). These
AID/APOBEC mutational signatures were found in cancers of the breast, bladder,
cervix, and hematopoietic origins.
The goal of this research project is to examine the genomic uracil load
introduced by AID both in normal activated B cells as well as in B cell lymphomas
and leukemias from patients and cell lines. Since AID can act on non-Ig genes,
one may predict an increase in the uracil load in the DNA of transformed
lymphocytes versus normal B cells. Furthermore, most studies that have
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analyzed the effects of AID on B cell cancers have only examined mutation or
base substitutions, the indirect consequence of AID activity. Innovatively, the
direct product of AID deamination, uracil, is studied and quantified here for the
very first time in several B cell cancer and normal genomes. To achieve this goal,
a very sensitive biochemical method that I have adapted and optimized was
implemented in these studies. This uracil quantification assay uses E. coli UNG
to remove the uracils in the genomes under study, resulting in abasic sites where
the uracils once were located. Aldehyde-Reactive Probe (ARP) is then used to
biotinylate these remaining abasic sites and a streptavidin conjugated to a
fluorophore can then label the biotins. This allows for sensitive detection and
quantification of uracil sites from the fluorescence signal intensities when a
standard containing known uracil amounts is processed in parallel. To elucidate
the difference between AID in cancer and AID in normal activated B-cells
undergoing antibody maturation, it is important to examine the AID- generated
uracils in both contexts.
This work also methodically and systematically analyzes the direct and
indirect types of DNA damage and genomic instability that may be promoted by
AID in B cell lymphoma cell lines. Since AID is an endogenous source of DNA
damage unlike most mutagens and carcinogens, the types of damages analyzed
here are those predicted to arise in the cell as a consequence of its attempt to
repair uracils. For example, the base excision repair machinery of the cell will
attempt to remove uracils in the genome through excision with proteins such as
UNG. This will result in an abasic site that can be processed by APE which nicks
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the DNA (see Figure 9). The study described here examines uracils that AID
introduces into the genome, abasic sites that uracil excision proteins create, and
strand breaks that may result from nicks created by APE. Findings that can
correlate these types and amounts of damage with factors such as AID and uracil
repair protein expression as well as lymphoma origin will be instrumental in
understanding B-cell lymphoma development. In addition many forms of
chemotherapy, such as the use of alkylating agents, aim at creating genomic
instability. Therefore by methodically testing the types of DNA damage already
present in B cell lymphomas due to endogenous factors, new combination
therapy aimed at exacerbating forms of genomic instability detected in this study
will be important from a clinical aspect. These types of DNA damage are
important as the initial uracil and its subsequent repair may lead to mutations and
translocations known to promote lymphoma development.
1.4.1 Rationale
This research provides new prospects for an early detection marker for B
cell lymphomas. The quantification of uracils in the genomes of patient B cells
may serve as an indicator of lymphoma development. In addition, knowledge of
the specific types of DNA damage in lymphomas that accumulate due to AID
activity can be used to develop new chemotherapeutic strategies that are aimed
at exploiting and further intensifying these genomic instabilities with the use of
specific DNA damaging agents. Patient samples from several lymphoma types
were assessed for these reasons. Finally, an understanding of the extent of
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genomic instability that AID creates may elucidate if AID should be a candidate
target in treatment strategies.
1.5 Specific Aims of Research
AIM 1) The extent of global genomic uracil introduction by AID and the removal
of uracils by repair enzymes in normal stimulated B cells are examined for the
first time. Genomic uracils are quantified using a sensitive biochemical uracil
detection assay to elucidate genome-wide AID activity in adaptive immunity.
Although the deamination of cytosine to uracils in single-stranded DNA by
AID is accepted in the field, there are no previous studies directly quantifying
uracils and demonstrating AID’s full capacity to introduce uracils in the entire
genome. The two previous studies of uracils introduced by AID have centered
only on the Ig gene in murine B cells (163, 164) and used an indirect method for
quantification, ligation mediated PCR (LM-PCR). Here, a sensitive uracil
quantification assay is implemented to directly determine the global genomic
uracil load that AID imposes on murine splenocytes and human tonsil B cell
genomes. Murine B cells from transgenic mice deficient in uracil repair proteins
are used to determine which repair enzyme is the primary contributor to the
removal of genome wide uracils introduced by AID undergoing the GC reaction.
This study has revealed that in normal B cells a homeostasis, dependent on
UNG, keeps uracil levels in the genome from accumulating despite AID activity.
AIM 2) The AID-dependent uracils in B cell lymphomas and uracil removal
capabilities are examined to determine differences in genomic uracil homeostasis
in cancer cells where AID is constitutively and ectopically expressed.
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The genomic uracils in B cell lymphomas are quantified using a sensitive
biochemical uracil detection system to determine the full extent of genome-wide
deamination by AID. This study has identified differences that exist in the total
genomic uracil load of normal activated B cells with up regulated AID levels
required for antibody maturation, contrasted with cancerous cells where AID is
ectopically or constitutively expressed. The genomes of several cancerous
samples and tissues including patient lymphomas were assessed and compared
to normal tissues. In addition, the expressions of AID and uracil repair proteins
such as UNG in lymphomas of GC- or post-GC origins were examined. The
results suggest that the homeostasis between AID- created uracils and UNGmediated excision seen in normal activated B-cells (AIM 1) is disrupted in
transformed cells that continue to overexpress AID.
AIM 3) Multiple types of DNA-damage that accumulate as a direct or indirect
consequence of the constitutive expression of the endogenous mutator enzyme,
AID, are identified and analyzed in B-cell lymphomas.
The mutagenic potential of uracil in U•G mispairs has been exploited as
an intermediate lesion in the adaptive immunity of mammals. The purposeful
introduction of uracils in the Ig gene by AID produces mutations and strand
breaks required for efficient antibody affinity maturation in B-lymphocytes.
However, when AID is ectopically expressed or aberrantly targets non-Ig genes,
several downstream pathways that attempt to repair these uracils can in fact lead
to further genomic instability. Unlike in the Ig-gene where point mutations are
welcomed for SHM to be effective, and double-strand breaks are necessary for
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CSR to generate appropriate isotypes, point mutations and strand breaks in other
genes may be detrimental to the cell or lead to transformation events. If AID is
constitutively overexpressed in B-cell lymphomas and is able to mutate the
genome, multiple types of damage may accumulate. This is essential to our
understanding of lymphoma development and in effective treatment strategies
because AID is an endogenous enzyme that is introducing the sources of DNA
damage studied here. To characterize these direct and indirect types of AIDdependent damage to the genome, several methods were applied to test the
genomes of B-cell lymphomas for viability, uracil accumulation, AP site
acquisition, and single- and double-strand breaks. Furthermore, this work led to
novel findings concerning the genomes of inviable lymphoma cells.
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CHAPTER 2: EXPERIMENTAL PROCEDURES
Portions of the text in this chapter were reprinted or adapted in compliance
with the ASM Journals Statement of Authors’ Rights from:

Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS.
Genomic uracil homeostasis during normal B cell maturation and loss of this
balance during B cell cancer development. Molecular and cellular biology.
2014;34(21):4019-32. doi: 10.1128/MCB.00589-14.
2.1 Overview of Materials and Methods
In order to study several aspects of the role of activation-induced
deaminase (AID) in normal B cell maturation and lymphomas, several tissues
were selected for this research including cell lines of germinal center-derived B
cell lymphoma origin, mouse tissues such as wildtype and transgenic AID-/- mice,
and several patient samples spanning different types of B cell cancers . All
protocols involving the use of animals and human tissue materials were subject
to Institutional Animal Care and Use Committee (IACUC) and Human
Investigation Committee (HIC)- Institutional Review Board (IRB) approval. To
accomplish the aims in this research, a sensitive biochemical genomic uracil
detection method is used in this research and described in detail in this section.
With this powerful tool, the genomic uracil levels in several tissues were
examined and compared to AID activity and mRNA levels, and uracil repair
enzyme activity and mRNA levels (see Figure 15 for an overview).
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Figure 15: Flow chart of the Tissues Assayed

Figure 15: Flow chart of the Tissues Assayed. Messenger RNA, genomic
DNA, and nuclear and whole cell protein extracts are purified from mouse tissues
(Top panel), and human lymphoma patient samples, tonsils, normal B
lymphocytes and cell lines (Bottom panel) and tested as described throughout
Section 2.1.
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To systematically assess the types of DNA-damage that accumulate in
lymphomas directly or indirectly due to AID, specific types of DNA damage were
assessed based on the subsequent in vivo processing of uracils introduced by
AID. Cell lines were assayed for a.) viability in culture, b.) AID expression, c.)
genomic uracil content, d.) abasic site accumulation, e.) single- strand and
double- strand DNA breaks. This was carried out utilizing an array of sensitive
techniques described here. Several molecular biology techniques are employed
in this research including quantitative real-time PCR, nuclear and whole cell
activity assays, non-liposomal transfections, transductions, electroporation, and
short-hairpin knock down of genes to study factors such as AID expression and
catalytic activity.
2.1.2 Tissue Samples and Materials for Study
2.1.2a Mouse Genetic Backgrounds and Tissue Harvest
Mice colonies were maintained at the University of Toronto and at Wayne
State University. Experiments involving animals were performed at the University
of Toronto and at Wayne State University and were approved by the Ethical
Committee for Animal Experimentation at the University of Toronto (Toronto,
Canada) and by the Institutional Animal Care and Use Committee (IACUC) at
Wayne State University (Detroit, Michigan), respectively. Breeding pairs of AID-/mice were kindly provided by Patricia Gearhart (National Institute on Aging) to
generate our colony (165).
Spleen, liver, and kidney tissues were harvested from twelve to eighteen
week old C57BL/6 background mice including wildtype mice (WT, control) and
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the following transgenic mice: UNG-/-, AID-/-, and MSH2-/- mice. Single-cell
suspensions of splenocytes, hepatocytes, and kidney cells were obtained by
filtering homogenized tissue samples through a 70-µm nylon-mesh (Corning,
Falcon). Kidney cells and hepatocytes were directly used for control studies.
Splenocytes were cultured in RPMI-1640 media (HyClone) supplemented with
10% fetal bovine serum (HyClone) and 50µM β-mercaptoethanol (Sigma-Aldrich)
for ex vivo stimulation time course studies (165).
AID-/-UNG-/- mice were generated at Wayne State University by crossing
AID-/- female mice with UNG-/- male mice in a trio breeding format.
Approximately thirty AID+/-UNG+/- mice (F1) were generated. F1 male mice
were then bred with F1 female mice (trio breeding) which generated
approximately 150 offspring (F2). Genotyping of F2 progeny was carried out with
PCR and 1/25 of F2 mice were detected as AID/-UNG-/-. See TABLE 3 for PCR
primers used for genotyping (165). Mice with undesired genotypes were donated
to Division of Laboratory Animal Resources (DLAR) for training purposes as
needed, or euthanized using approved IACUC protocols.
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TABLE 3: Primers used to Genotype Mice

Gene

5’ Primer

WT AID

AID-811

AID-G4

5’CTGAGATGGAACCCTAACCTCAGCC

5’CACGATTTTCTACAAATGTATTCCAGC

disrupted
AID
allele
WT UNG
disrupted
UNG
allele

AID-G3
5’GGGCCAGCTCATTCCTCCACTC

3’ Primer

AID-G4
5’CACGATTTTCTACAAATGTATTCCAGC

Up 310

Lower 18

5’GCCCATCTTGGAAACTCAAA

(5’CCAGTCTGGCTTGGTTACCTTG)

Up 310

Neo1524R

5’GCCCATCTTGGAAACTCAAA

5’CGTCAAGAAGGCGATAGAA

TABLE 3: Primers used to Genotype Mice during generation of AID-/-UNG-/double knockout colony.
2.1.2b Murine and Human Cell Lines
The murine cell line, J558, is a plasmacytoma cell line that was obtained
from American Type Culture Collection (ATCC, Rockville, MD).The mouse B cell
lymphoma cell line, CH12F3.2 and the heterozygous and homozygous AID
knock-out lines, CH12F3.2 AID+/- and AID-/-, respectively, were kindly provided
by Kefei Yu (Michigan State University).
Several human T- and B- lymphocyte cancer cell lines were obtained for
these studies. The Epstein-Barr virus (EBV-) negative Burkitt-Lymphoma cell
lines, Ramos 1 and Ramos 7 were previously referred to as Ramos clone 1-12
and Ramos clone 7-3 respectively and were kindly provided by A. Martin
(University of Toronto)(166). Ramos-derived cell lines C.1, A.1, A.2, and A.5
have also been described (6). The human B cell follicular small cleaved cell
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lymphoma line (WSU-FSCCL) (167) and the human diffuse large B cell
lymphoma line (WSU-DLCL2) (168) were established in the laboratory of Dr.
Ayad Al-Katib. The human Hodgkin lymphoma cell lines (KM-H2, L-428, L-591)
and WSU-CLL were obtained from DSMZ (Germany). The Epstein-Barr virus
positive (EBV +) Burkitt Lymphoma cell lines, Raji and Daudi, the human diffuse
lymphoma cell lines, RL and Toledo, and acute T cell leukemia and lymphoblastlike cell lines (Jurkat and CEM, respectively) were obtained from ATCC. TABLE 4
summarizes the cell lines used in this work.
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TABLE 4: Mammalian Cell Lines
Number

Name of
Cell Line

Lymphoma/Leukemia
Type

Source

1

Jurkat

Human Acute
T Cell Leukemia

American Type Culture
Collection (Rockville, MD)

2

CEM

Human Acute T Cell
Lymphoblastic Leukemia

Leibniz‑Institut DSMZ
(Germany)

3

L591

Human Classical
Hodgkin’s Lymphoma

Leibniz‑Institut DSMZ
(Germany)

4

L428

Human Classical
Hodgkin’s Lymphoma

Leibniz‑Institut DSMZ
(Germany)

5

KMH2

Human Classical
Hodgkin’s Lymphoma

Leibniz‑Institut DSMZ
(Germany)

6

ARP1(169)

Human Multiple Myeloma

Wayne State University,
Detroit, USA

7

FSCCL(167)

Human Follicular, Small
Cleaved Lymphoma

Dr.Al‑Katib, Wayne State
University, Detroit, USA

8

WSU-NHL
(170)

Human Follicular, Large
Cell Lymphoma

Dr.Al‑Katib, Wayne State
University, Detroit, USA

9

DLCL2(168)

Human Diffuse Large B
Cell Lymphoma

Dr.Al‑Katib, Wayne State
University, Detroit, USA

10

Toledo

Human Diffuse Large B
Cell Lymphoma

American Type Culture
Collection (Rockville, MD)

11

RL

Human Diffuse Large B
Cell Lymphoma

American Type Culture
Collection (Rockville, MD)

12

Raji

Human EBV+ Burkitt
Lymphoma

American Type Culture
Collection (Rockville, MD)

13

Daudi

Human EBV+ Burkitt
Lymphoma

American Type Culture
Collection (Rockville, MD)
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TABLE 4: Mammalian Cell Lines (continued)
Number

Name of
Cell Line

Lymphoma/Leukemia
Type

Source

-

J558

Mouse plasmacytoma

American Type Culture
Collection (Rockville, MD)

-

CH12F3.2

Mouse B-cell Lymphoma

Kefei Yu (Michigan State
University)

-

Ramos

Human EBV- Burkitt
Alberto Martin
Lymphoma
(University of Toronto)
Numbers in red correspond to figure labels in chapter 3 for cell lines indicated.
TABLE 4 was originally published in the supplementary material for (165)
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and
loss of this balance during B cell cancer development. Molecular and cellular
biology. 2014;34(21):4019-32. Adapted from the American Society for
Microbiology.
2.1.2c Isolation of Peripheral B Cells from Healthy Donor Blood
Normal B cells were isolated from healthy American Red Cross (ARC)
donors using peripheral blood collected in apheresis cones and filters. ARC
donor blood was kindly provided by Dr. Martin Bluth (Associate Director of Detroit
Medical Center Transfusion Services). Peripheral blood mononuclear cells
(PBMCs) were first separated from the granulocyte and erythrocyte populations
using Ficoll-Paque Premium density-gradient media (GE Healthcare, Stem Cell
Technologies). B cells were initially isolated from the PBMCs using negative
selection.

A cocktail of biotinylated antibodies specific for surface markers

present on non-B cells, including natural killer (NK) cells, T lymphocytes,
dendritic cells, and monocytes was used for labeling the cells (human B cell
Isolation Kit II, MACS, Miltenyi Biotec). The non-B cells were depleted from the
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pool by using magnetically labeled anti-biotin beads. Highly pure B cell
populations were confirmed with flow cytometry or purified as needed with FACS.
2.1.2d Cancer Patient Tissues
Ethical consideration for the use of patient samples in this research was
approved following review by the Human Investigation Committee and the
Institutional Review Board (IRB) at Wayne State University School of Medicine.
Following informed consent, peripheral blood was collected from lymphoma
patients during the leukemic phase under the clinical care of Dr. Ayad Al-Katib at
St. John Hospital Van Elslander Cancer Center Lymphoma Clinic. Some patient
B cells were purified from thigh lesion biopsies, lymph node biopsies, or pleural
effusions. No identifying patient markers or information was retained. PBMCs
were purified from patient whole blood using LymphoPrep density gradient media
(ProGen Biotechnick GmbH, Germany). The total monocyte cell population was
depleted from the PBMC suspension cells through adherence to the sterile
plastic surface of tissue culture flasks. The non-adherent lymphocyte pool of cells
was collected and B cells isolated through removal of T lymphocytes using
magnetic bead separation with Dynabeads pan CD2 (Dynal, Life Technologies,
Grand Island, NY). FACS analysis for each patient sample confirmed the
recovery of ~95% B cells. These purified B cell populations were utilized in
expression analysis and genomic uracil quantification studies (165). TABLE 5
summarizes the patient lymphoma samples, p53 status, and karyotypes.
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TABLE 5: Lymphoma/Leukemia Patient Summary
Number

Age

Sex

Race

Type of
Lymphoma/
Leukemia

Cytogenetics/
Karyotype

P53
Status

P1

81

F

Caucasian

CLL/SLL

58.5% deleted13q

WT
WT

P2

76

M

Caucasian

CLL/SLL

84.5% trisomy 12;
15.5% deletion of
17p; 11%-loss of
IgH locus

P3

71

F

Caucasian

CLL/SLL

67.5% trisomy 12

WT

CLL/SLL

86.5% deleted 13q

WT

P4

64

F

AfricanAmerican

P5

62

M

Caucasian

MZL

Normal/46,XY [20]

WT

P6

86

M

Caucasian

MZL

Normal/46, XY [20]

WT

P7

72

M

Caucasian

MZL

45% t(2;7)
(p12;q21‑22)

WT

P8

61

F

Caucasian

DLBCL

Normal/46, XX [20]

WT

P9

49

F

Caucasian

FL

23% t(14;18)
(q32; q21.3)

WT

P10

87

F

Caucasian

FL

55% Complex
chromosomal
arrangements;
t(3,11)(q27;q11);
t(14;18)(q32;q21.3
)+
der(18); IgH‑BCL2
fusion

WT
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TABLE 5: Lymphoma/Leukemia Patient Summary (continued)
Number

Age

Sex

Race

Type of
Lymphoma
/Leukemia

Cytogenetics/
Karyotype

P53
Statu
s

P11

64

F

Caucasian

CLL/SLL

54.5% deleted 13q

WT
Mt

P12

69

F

Caucasian

CLL/SLL

51% deleted 13q;
9% deleted 17p

P13

62

M

Caucasian

CLL/SLL

23.5% deleted
13q; 26% 3 IgH
copies

WT

P14

69

F

Caucasian

CLL/SLL

72% deleted 13q

WT

(K132R
)

TABLE 5 was originally published in the supplementary material for (165)
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and
loss of this balance during B cell cancer development. Molecular and cellular
biology. 2014;34(21):4019-32. Adapted from the American Society for
Microbiology.
2.1.2e Flow Cytometry for the Isolation of Human naïve mature B Cells from
Healthy Tonsil Tissues
Healthy tonsil tissues were acquired as discarded surgical samples from
patients with no identifying markers that underwent resection of hypertrophic
tonsils at Children’s Hospital of Michigan. Tonsils were approved for use in this
research by the Institutional Review Board of Wayne State University. Tonsils
were obtained with the assistance of Dr. Kang Chen (Barbara Ann Karmanos
Cancer Institute and the Perinatology Research Branch, NICHD, NIH).
Tonsillar tissue was first filtered through a 70-µm nylon-mesh (Corning,
Falcon) to yield a single-cell suspension in RPMI-1640 supplemented with
gentamicin (HyClone). The PBMC fraction was collected using Ficoll-Paque
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Premium density- gradient media (GE Healthcare, Stem Cell Technologies).
Naïve mature B cells were purified by FACS with IgD-FITC (Southern Biotec
2032-02), CD19-PECy7 (eBioscience 25-0199-42), CD38-APC (Biolegend
303510), and CD27-PE (BD 555441) to yield IgD positive, CD19 positive, CD38
negative, and CD27 negative B lymphocytes. Dead cells were excluded during
FACS collection by 7AAD (BD 559925) labeling. The purified naïve mature B cell
population was cultured ex vivo in RPMI-1640 (HyClone) media supplemented
with 10% FBS (HyClone) and 1% P/S at 37oC and 5%CO2. B cells were activated
to express AID and undergo CSR by adding 500ng/ml of CD40-L (Peprotech)
and 50ng/ml of IL-4 (Peprotech) and culturing for seven days. Class switching
from IgM to IgG1 was confirmed with appropriate antibody labeling and FACS.
(165).
2.1.3 Propagation of Cells
2.1.3a Cell Line Maintenance and Activation
J558 was cultured in DMEM (HyClone) supplemented with 10% fetal
equine serum (FES, HyClone) and 1% P/S. All CH12F3.2 cells were cultured in
suspension in RPMI-1640 media supplemented with 10% FBS, 50µM βmercaptoethanol, and 1% P/S. CH12F3.2 cells were chosen for this study
because the wildtype cell line expresses AID upon stimulation with a cocktail of
cytokines and switches from IgM isotype to IgA (1). WT CH12F3.2 AID +/+ and
the heterozygous and homozygous knock outs, AID +/- and AID -/-, were
stimulated with CIT. Specifically cells were treated with 1 ug/mL of purified antimouse CD40 (eBiosciences), 10 ng/ml of recombinant mouse IL-4 (R&D
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systems) and 1 ng/ml of recombinant human TGFβ1 (R&D Systems). Class
switching to IgA was analyzed and confirmed by flow cytometry. All of the human
T- and B- cell lines listed in TABLE 4 were cultured in suspension in RPMI-1640
media supplemented with 10% FBS and 1% P/S. Cells were incubated at 37oC
and 5% CO2 in a humidified incubator in T-25cm2 flasks, T-75cm2 flasks, 96-well,
24-well, 12-well or 6-well sterile plates (Corning).
2.1.3b Ex vivo Stimulation of Splenic Murine B cells
In ex vivo stimulation time course studies, primary splenocytes from WT,
AID-/-,

UNG-/-,

and

MSH2-/-

mice

were

treated

with

25

µg/ml

of

lipopolysaccharide (LPS, E. coli serotype 055:B5; Sigma-Aldrich) to induce
isotype switching of B cells to IgG3. Switching of primary B cells was confirmed
with flow cytometry (165).
2.1.4 RNA Extraction and Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted from human and murine primary B lymphocytes
and cell lines using Trizol (Invitrogen) per manufacturer’s protocols and
instructions. Total RNA was reverse transcribed with anchored oligo-dT primers,
specifically d(T)23VN where V is A, G, or C and N is A, G, C, or T and the
ProtoScript M-MuLV First Strand cDNA Synthesis Kit (New England Biolabs).
cDNA was amplified with HotStart Taq polymerase and RT2 SYBR Green/ROX
(SA Biosciences, Qiagen) to quantify relative gene expression. qRT-PCR was
performed with Applied Biosystems 7500 Fast Real Time PCR System and the
expression levels were determined using the delta Ct method with GAPDH or
TBP as a reference gene.
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TABLE 6: Primers for qRT-PCR
Gene
Murine
AID
Murine
UNG2
Murine
SMUG1
Murine
TDG
Murine
MBD4
Murine
GAPDH
Human
AID
Human
UNG2
Human
SMUG1
Human
GAPDH

5’ Primer Sequence

3’ Primer Sequence

5’GAAAGTCACGCTGGAG

5’TCTCATGCCGTCCCTT

5’GTCTATCCGCCCCCGGAGCA

5’TGGGCGGGGGTGGAACT

5’GAGTGCTGGGATTAAAAGGAT

5’CCAGAATGGGACAAGGATA
G

5’GTCTGTTCATGTCGGGGCTGA
GTG

5’CTGCAGTTTCTGCACCAGG
ATG

5’TGGAGCTGCAGCTGCGCCCC
A

5’CTGCGCTCACTGCTTATCAC
C

5’ACCACAGTCCATGCCAT

5’TCCACCACCCTGTTGCTGTA

5’AGAGGCGTGACAGTGCTACA

5’TGTAGCGGAGGAAGAGCAA
T

5’CCTCCTCAGCTCCAGGATGA

5’TCGCTTCCTGGCGGG

SA Biosciences (PPH02717A)

SA Biosciences (PPH02717A)

5’TGCATCCTGCACCACCAACT

5’CGCCTGCTTCACCACCTTC

TABLE 6 was originally published in the supplementary material for (165)
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and
loss of this balance during B cell cancer development. Molecular and cellular
biology. 2014;34(21):4019-32. Adapted from the American Society for
Microbiology.
2.1.5 Trypan Blue Exclusion Assay
2.1.5a Percent Viability
Cell lines were first stained with Trypan Blue (HyClone) and counted using
a TC20 Automated Counter (BioRad) to determine the percentage of viable cells.
Inviable cells were removed from cell lines determined to have <95% viability
using the Dead Cell Removal Kit (MACS, Miltenyi Biotec) to start each cell line at
>95% viability at “Day 0.” After three days of incubation, cells were stained with
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Trypan Blue and counted to determine percent cell viability. This was repeated in
six individual T-25cm2 flasks per cell line tested.

2.1.5b Separation of Dead/Dying Cells from Viable Cells
To separately analyze the genomic uracil load in viable and inviable cell
populations, dead/dying cells were isolated from viable cells using the Apoptotic
Cell Isolation Kit (Promokine) which utilizes Annexin V magnetic beads that have
a high-affinity for the phosphatidylserine that dead/dying cells redistribute to the
outer surface of their plasma membrane. Genomic DNA was prepared from the
separated populations for uracil quantification (see Figure 16 for schematic).

Figure 16: Isolating Inviable Cells from Viable Cells

Figure 16: Isolating Inviable Cells from Viable Cells. Only dead/dying cells
with surface phosphatidylserine are labeled with Annexin V conjugated to biotin.
These cells are then isolated from the pool of cells with streptavidin-conjugated
magnetic beads.
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2.1.6 Quantification of Apurinic/Apyrimidinic Sites in DNA
Abasic sites, or AP sites, are quantified by adapting a previously
described biochemical detection method (171). Genomic DNA is extracted from
cells using the Blood and Cell Culture Kit (Qiagen) or standard DNA extraction
protocols (172). High molecular weight DNA is then restriction digested with
HaeIII (New England Biolabs). The endogenous abasic sites in DNA are treated
with 2 mM aldehyde-reactive probe (ARP; Dojindo Laboratories, see Figure 17
and 18).
Figure 17: Aldehyde- Reactive Probe

Figure 17: Aldehyde- Reactive Probe. The structure of Aldehyde- Reactive
Probe (ARP) is depicted above. Figure created in ChemBioDraw Ultra 14.0
DNA is purified by ethanol precipitation, and filtering through a G-25
column (GE Healthcare) twice to remove residual reagents. DNA samples are
then quantified using a NanoDrop ND-2000c (ThermoScientific), and with
SYBRGold and a BioTek Synergy H1 Hybrid Microplate Reader or a Tecan
Genios Microplate Reader where concentrations were determined based on a
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standard calibration plot. Determined amounts of purified DNA samples are
applied onto a positively charged Immobilon-Ny+ Nylon membrane (Millipore)
using a vacuum-filtration apparatus (Bio-Rad Bio-Dot Vacuum Apparatus). The
membrane is pre-equilibrated in double-distilled H2O and 6X SSC (saline-sodium
citrate buffer) prior to DNA application.
Figure 18: Reaction of Aldehyde- Reactive Probe with AP Site

Figure 18: Reaction of Aldehyde- Reactive Probe with AP Site. The reaction
of an abasic site with aldehyde-reactive probe (ARP) leads to the biotinylation of
the site. Endogenous abasic sites are labeled this way in the quantification of AP
sites assay and AP sites generated by the removal of uracils by UNG are
biotinylated in this manner in the uracil quantification assay. ChemBioDraw Ultra 14.
After vacuum spotting the DNA onto the Ny+ membrane, it is incubated in
StartingBlock buffer (Fisher Scientific) to block non-specific binding, followed by
incubation in streptavidin-Cy5 (GE Healthcare) in the blocking buffer for one hour
at room temperature. The membrane is then incubated three times in TBS-T (25
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mM Tris, 3 mM KCl, 140 mM NaCl, 1% Tween-20) on a rocking platform to wash
residual fluorophore buffer and scanned using a Typhoon 9210 Phosphorimager
for Cy5 fluorescence. Cy5 fluorescence signal from samples and standard DNA
are analyzed with ImageJ software (see Figure 19 for a schematic outline of the
AP site quantification assay). To convert Cy5 fluorescence intensity signal to
number of AP sites per million base pair, duplex DNA is used to generate a
standard plot (see Section 2.1.7b Standard Plot).
Figure 19: Schematic Outline of AP Site Quantification in Genomic DNA

Figure 19. Schematic Outline of AP Site Quantification in Genomic DNA.
Digested DNA is treated with Aldehyde-Reactive Probe (ARP, Dojindo) to
biotinylate the persistent endogenous abasic sites. The DNA is vacuum
transferred onto a nylon membrane and incubated with streptavidin-Cy5. The
membrane is scanned to quantify fluorescence intensity and the signal is
converted into number of abasic sites using a duplex standard described in
2.1.7b Standard Plot.
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2.1.7 Quantification of Genomic Uracils
2.1.7a Total Uracils in DNA
To quantify the total uracils in the genomic DNA of mouse tissues, patient
samples, and cell lines, a modified ARP-detection method of a previously
described biochemical procedure is used (173-175). HaeIII (New England
Biolabs) restriction enzyme digested DNA was treated with 5 mM methoxyamine
(Mx, Fisher Scientific). This reacts with endogenous AP sites to block their
labeling in the subsequent ARP treatment step (see Figure 20). To remove
unbound or excess Mx, DNA is ethanol precipitated and filtered through a G-25
column (GE Healthcare).
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Figure 20: Reaction of Methoxyamine with AP Site

Figure 20: Reaction of Methoxyamine with AP Site. The reaction of an abasic
site with methoxyamine (MX) protects the AP site from later reacting with ARP
treatment and being biotinylated in the uracil quantification assay. All
endogenous abasic sites are blocked this way in the ensuring ARP labeled
abasic sites are only those that result from the excision of uracil by UNG. Figure
created in ChemBioDraw Ultra 14.0
The DNA is then treated with E. coli UNG (New England Biolabs) and 2
mM ARP for one hour at 37oC. UNG removes uracils in U:A base pairs, U•G
mispairs and uracils in single-stranded DNA (see TABLE 1). This allows for total
removal of genomic uracil and ARP labels the resulting AP sites that remain after
uracil excision with biotin (see Figure 18). This procedure ensures that detected
abasic sites are those resulting from uracil excision. The DNA is then extracted
with phenol: chloroform to remove the UNG enzyme, ethanol precipitated, and
passed over G-25 columns (GE Healthcare) similar to the AP site detection
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method. The DNA samples are quantified and spotted onto a Nylon membrane
and the Cy5 fluorescence detection procedure is identical to that described
above in 2.1.6 Quantification of Apurinic/Apyrimidinic (AP) Sites in DNA. See
Figure 21 below for a schematic outline of the total genomic uracil quantification
assay (165).
Figure 21. Schematic Outline of the Genomic Uracil Quantification Assay.

Figure 21. Schematic Outline of the Genomic Uracil Quantification Assay.
Digested DNA is treated with methoxyamine to block pre-existing abasic sites. E.
coli UNG is used to excise uracils and treatment with ARP biotinylates the
resulting AP sites. The DNA samples are vacuum transferred onto a nylon
membrane and incubated with Cy5- streptavidin. The membrane is scanned to
quantify fluorescence intensity and the signal is converted into number of uracils
using a duplex standard described in 2.1.7b Standard Plot. This figure was
originally published in the supplementary material for (165) Shalhout et al.
Genomic uracil homeostasis during normal B cell maturation and loss of this
balance during B cell cancer development. Molecular and cellular biology.
2014;34(21):4019-32. Reproduced from the American Society for Microbiology.
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2.1.7b Standard Plot
To quantify the AP sites per million base pair and Uracils (U) per million
base pair, a standard oligonucleotide duplex containing a single U:G mismatch is
used in both detection assays. The synthetic 75 base pair duplex DNA (IDT) has
the following sequence: Top Strand 5’-T37UT37; Bottom Strand 5’-A37GA37. The
oligos were PAGE purified and the 75mers were annealed (1:2 ratio of top:
bottom strand) and diluted to a final concentration of 2 x 1011 U per µL.
This duplex standard was treated with methoxyamine at 37oC for one
hour, followed by treatment with an excess of UNG (2 units per 0.5 µg of DNA)
and 2 mM of ARP for one hours at 37oC. To remove protein and unbound ARP,
the duplex is phenol:chloroform extracted and ethanol precipitated. It is then
reconstituted to give a final concentration of 1 x 1010 U per µl. Several dilutions of
this DNA are vacuum-applied to each Nylon+ membrane, in parallel with genomic
DNA tested for uracil content or AP site load. This allows for generation of a
calibration plot of Cy5 fluorescence versus uracil number (or AP site number ) for
every membrane with spotted test samples. See Figure 22 for a representative
standard plot. The raw fluorescence numbers are determined with ImageJ and
are adjusted for background fluorescence signal on each membrane. The
numbers of uracils or AP sites in the genomic DNAs are determined by
interpolating their fluorescence intensities using the calibration plot. These
amounts are normalized for the known amount of DNA loaded for each sample to
calculate the number of uracils or AP sites per 106 bp. The uracil amount
calculated is divided by the “control” DNA and allows for a ratio report. The
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control for tested murine samples was DNA uracil content level of WT mice
splenocytes or DNA from unstimulated CH12F3 cells. For human lymphoma cell
lines or patient tissue samples the control was B lymphocytes purified from the
blood of American Red Cross donors/volunteers (165).
Figure 22. Representative Standard Plot for Genomic Uracil and AP Site
Quantification Assay

Figure 22. Representative Standard Plot for the Genomic Uracil and AP Site
Quantification Assays. Top- A representative fluorescence scan of a Ny+
membrane with eight spots containing different amounts of the labeled uracil
containing duplex DNA ranging from 0 to 35 x 1010 total uracils. Bottom- A
representative plot of the fluorescence intensity of these spots as a function of
number of uracils in each DNA duplex spot. The genomic uracils or AP sites in a
mouse or human DNA sample is calculated by interpolating its fluorescence
intensity in plots like this generated from standards applied onto each membrane.
This figure was originally published in the supplementary material for (165)
Shalhout et al. Genomic uracil homeostasis during normal B cell maturation and
loss of this balance during B cell cancer development. Molecular and cellular
biology. 2014;34(21):4019-32. Reproduced from the American Society for
Microbiology.
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2.1.7c Uracils in U•G base pairs
The uracil quantification assay described above (section 2.1.7a)
determines the total uracil content of genomic DNA. This is because it uses E.
coli UNG to excise the uracils and this enzyme removes uracils from singlestranded DNA and from U:A base pairs in addition to excising uracils from U•G
and other mispairs. It is important, however, to specifically detect U•G mispairs
since AID introduces U•G mispairs by deaminating cytosines in C:G base pairs.
To detect just the uracils in U•G mispairs, the assay was altered to use the
second uracil-DNA glycosylase in E. coli, Mug. This enzyme is an ortholog of
mammalian thymine-DNA glycosylase (TDG, see TABLE 1) which selectively
removes uracils from U•G mispairs and has poor activity on uracils paired with
adenine (176). Purified MUG enzyme was used in place of UNG in the protocol
described in section 2.1.7a.
The U•G quantification assay protocol requires membrane processing,
fluorescence acquisition, and interpolation from a standard plot generated by
spotting dilutions of the duplex oligo exactly as used in the total uracil
quantification assay. To quantify only U:A bp, DNA was first treated with MUG to
remove all uracils in U•G bps, then treated with Mx to block these sites from
being biotinylated. After purification, the DNA is then treated with UNG which
removes the uracils left in the DNA that are in U:A bps only since previous MUG
treatment excised all uracils in U•G bps. The AP sites left after UNG removes
uracils opposite A are then labeled with ARP and the only uracils in U:A base
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pairs are calculated using a standard, similar to the protocol for AP site and total
uracil quantification.
2.1.8 Activity Assays with Whole Cell Extracts (WCE) and Nuclear Extracts (NE)
2.1.8a Cytosine Deamination Activity Assays
Protein preparations from whole cell extracts (WCE) were prepared from
~1 x 107 cells. Cells were centrifuged and the pellet was resuspended in buffer I
[10 mM Tris-HCL (pH 8.0)] and buffer II [10 mM Tris-HCl (pH 8.0), 200 mM KCl,
2 mM EDTA, 40% (v/v) glycerol, 0.5% NP-40, 2 mM DTT] with the addition of
protease inhibitor (Halt Protease Inhibitor Cocktail, Thermo Scientific). The cells
were then incubated at 4ºC for 3 hours with gentle agitation and cellular debris
was pelleted at 25,000 g at 4ºC. Cell-free protein extract was recovered in the
supernatant. Nuclear extracts of ~1 x 107 cells were prepared with the NucBuster
Protein Extraction Kit (Novagen, Millipore) according to the manufacturer’s
instructions with the addition of three extra washes of each nuclear pellet
preparation to ensure no cytoplasmic protein contamination occured during
preparation. Whole cell and nuclear protein concentrations were measured using
the Bio-Rad protein assay and extracts were snap frozen in liquid nitrogen and
stored at -80ºC.
To assay AID deamination activity in protein preparations, 8 pmols of a 5’
6-FAM labeled oligo containing AID’s preferred sequence (WRC, where W=A/T,
R=purine, 5’-ATTATTACCCATTTATT) was incubated with whole cell or nuclear
cell extracts for 30 minutes with RNaseA (1 µg), in the following reaction buffer:
10 mM Tris⋅HCl, pH 7.5, 1 mM EDTA/1 mM DTT, 150mM NaCl. Reactions were
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incubated at 37°C with a total reaction volume of 20µl and were terminated by
the addition of 1, 10-phenanthroline (Sigma–Aldrich) to 5 mM. UNG (0.5 units)
was added to the reactions to excise any uracils introduced by AID deamination
and incubation was continued at 37 °C for 60 min. Any abasic sites resulting from
uracil excision were nicked by the addition of 0.1M NaOH and incubation at 95
°C for 5 min. See section 2.1.8b for reaction product analysis and specific activity
reports (165).
2.1.8b Uracil Excision Activity Assays
To assay uracil excision activity, 24 pmols of a single-uracil containing 6FAM labeled oligomer (5’- ATTATTAUCCATTTATT) is incubated with whole cell
or nuclear cell extracts for ten minutes at 37ºC in a 20µl total reaction with 1 mM
EDTA, 1 mM DTT, and 20mM Tris-HCl (pH 8.0) with or without excess Uracil
DNA-Glycosylase Inhibitor (UGI,New England Biolabs). A single-strand substrate
is used to avoid detection of uracil excision activity from TDG and MBD4 which
prefer to remove mispaired uracil from duplex DNA. Reactions are stopped at
95ºC for 5 minutes followed by incubation with Proteinase K (Qiagen) for 60
minutes at 50ºC. Abasic sites are incised using 0.1 mM NaOH treatment at 95ºC
for five minutes. Reaction products for AID deamination assays (section 2.1.8a)
and uracil excision assays are analyzed by electrophoresis (15% PAGE, 7M
Urea, Tris-Borate-EDTA buffer), and a Typhoon 9210 Scanner is used to
visualize products. Quantification of activity is determined with ImageJ Gel
Analysis Software and specific activity is reported as pmols of product/min/µg of
protein (165).
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2.1.9 Assays for Single-Strand and Double Strand Breaks in DNA
2.1.9a Comet Assays and Tail moments
The comet assay or single-cell gel electrophoresis is utilized in this study
to detect strand breaks in the genomic DNA of lymphoma cell lines expressing
AID. This technique requires electrophoresing cells that are embedded in lowmelting agarose and visualizing by fluorescence microscopy. The alkaline comet
assays were performed using the Comet Assay Silver Kit (Trevigen) according to
manufacturer’s instructions. Tail moments were quantified using Image J and
these experiments were carried out by a collaborator (A. Martin, University of
Toronto).
2.1.9b Immunofluorescence of γH2AX Foci and Quantification of Foci per
Nuclei
Cells were harvested by centrifugation and cell pellets were then
resuspended in a hypotonic solution and incubated at 37oC for five minutes.
Approximately ~500 cells were spun onto microscope slides (Fisher) using a
StatSpin Cytofuge. They were fixed with ethanol:acetic acid, blocked with 3%
rabbit serum (Hyclone) in PBS to reduce non-specific secondary antibody
binding, and treated with mouse monoclonal anti-phospho-histone H2A.X
(Ser139) antibody (Millipore; 05-636). The slides were washed in PBS two times,
followed by treatment with rabbit anti-mouse IgG antibody conjugated to Cy3
(Millipore; AP160 C). The slides are washed in PBS and mounted with coverslips
using VectaShield Mounting Medium with DAPI. Cells were visualized and
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photographed using a fluorescence microscope (Nikon 80i). The foci per nuclei
were quantified using ImageJ. Untreated normal B cells and cells treated with 50
µg/ml zeocin (Invitrogen) served, respectively, as negative and positive controls
for γH2AX foci analysis.
2.1.10 Short-hairpin RNA (shRNA) Knockdown of Expression in Lymphoma Cell
Lines
AID expression was knocked down in AID expressing lymphoma cell lines
using shRNA plasmids obtained from SA Biosciences (SureSilencing shRNA
plasmids for human AICDA for neomycin resistance, KH12741N). Transfection
grade plasmids were prepared with HiSpeed Plasmid Maxi Kit (Qiagen). Cell
lines were either electroporated using a Gene Pulser Xcell (BioRad) or
transfected with shRNA-AID and shRNA-scrambled using FuGeneHD (Promega)
depending on cell line optimization conditions. Stable clones of shRNA-AID and
shRNA-scrambled cell lines are selected with G418 (HyClone).
2.1.11 Expression of Uracil DNA-Glycosylase Inhibitor in Lymphoma Cell
Lines to reduce Uracil Excision by UNG
To inhibit uracil DNA-glycosylase activity, human B cell lymphoma cell
lines were transfected with pEF (control) and pEF-UGI plasmids by
electroporation (Gene Pulser Xcell). Cells were diluted in appropriate media and
plated into 96-well plates. Following 24- 48 hr incubation at 37ºC, stable clones
were selected with puromycin (Promega).
2.1.12 Transient Expression of E58A and WT AID in Ramos 1 Cell Line
Approximately two million Ramos 1 cells were transfected with
transfection grade pMSCV-EV (empty vector), pMSCV-E58A, and pMSCV-AID
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isolated with HiSpeed Plasmid Maxi Kit, (Qiagen) using FuGeneHD (Promega)
and selected with 2 µg/ml of puromycin (Gibco). The pmax-GFP (Amaxa Lonza)
plasmid was used to track transfection efficiency with FuGene of the transient
clones.
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CHAPTER 3: RESULTS
Figures and portions of the text in this chapter were reprinted or adapted
in compliance with the ASM Journals Statement of Authors’ Rights from:
Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS.
Genomic uracil homeostasis during normal B cell maturation and loss of this
balance during B cell cancer development. Molecular and cellular biology.
2014;34(21):4019-32. doi: 10.1128/MCB.00589-14.
3.1 AIM 1- Genomic Uracils in Normal Activated B cells
The extent of global genomic uracil introduction by AID and the removal of
uracils by repair enzymes in normal human and murine stimulated B cells are
examined for the first time here. Genomic uracils are quantified using a sensitive
biochemical uracil detection assay to elucidate genome-wide AID activity in
adaptive immunity.
Splenocytes from wildtype C57BL/6 mice were harvested and stimulated
ex vivo with LPS to closely mimic the activation involved in the normal
development of B cells during the GC- reaction. Upon activation with LPS, the
cultured splenocyte population was ≥ 85% B cells shown with flow cytometry.
For comparison, splenocytes from AID-/- transgenic mice were stimulated in the
same manner as a negative control for AID-generated uracils. Splenocytes from
UNG-/- and MSH2-/- transgenic mice which are deficient in two separate repair
proteins thought to play roles in SHM and CSR were also used in this study to
determine the effects of these proteins on processing the uracils AID introduces
during activation of B cells. Finally, splenocytes from AID-/-UNG-/- mice were
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also tested to demonstrate that the detected uracil content is AID-dependent.
The total cellular DNA from these cells was isolated and the uracils quantified as
described in section 2.1.7. DNA from unstimulated splenocytes of each mouse
background was extracted and also tested for uracil content as ‘non-activated’ B
cell controls. Liver and kidney tissues were also harvested and single cell
suspensions from these tissues were studied as the ‘non-B cell’ controls. These
experiments were designed to determine the amount of genomic uracil that is
AID-dependent and to elucidate which uracil repair enzyme is primary in global
genomic uracil removal during the normal GC- reaction of murine B cells.
3.1.1 Genomic Uracil Quantification of Activated Murine B Cells
An image of a Cy5 fluorescence scan of a nylon membrane from one
representative experiment is shown in Figure 23 where equal amounts of DNA
from ex vivo stimulated splenocytes under LPS treatment for 3 days were
spotted. In this and all other uracil quantification studies, different known
amounts of a duplex containing a U•G mispair were also processed in parallel
and applied to the membrane to generate a calibration plot as depicted in Figure
22 (see section 2.1.7b for details). Cy5 fluorescence signals from genomic DNA
of mice with different genetic backgrounds were converted to uracil amounts
using the calibration plot, and then uracil amounts in WT splenocytes prior to
stimulation were used to calculate the fold increases in uracil levels. The
scanned image strikingly reveals the highest Cy5 fluorescence intensity and
therefore uracil content in DNA samples from UNG-/- splenocytes stimulated for
3 days. DNA from UNG-/- unstimulated splenocytes and hepatocytes also
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contain slightly higher fluorescence intensity compared to other genetic
backgrounds due to the general lack of UNG available for removal of uracils
introduced in AID-independent pathways (see Figure 10). The quantified results
from a typical experiment are presented in Figure 24 A and B.
Figure 23. Representative Nylon Membrane used in Quantifying Genomic
Uracils in WT and Transgenic Murine DNA

Figure 23. Nylon Membrane used in Quantifying Uracils in Murine DNA. A
representative mage of a fluorescence scan of a representative nylon membrane
with equal DNA amounts spotted from triplicate samples of unstimulated murine
splenocytes (-LPS) and splenocytes stimulated with LPS (+LPS) for 3 days. The
splenocytes were obtained from WT mice and mice with the indicated genetic
backgrounds. DNAs were labeled with Cy5 at sites of uracils as described in
Figure 21. Liver DNAs from the same mice served as negative controls. As
shown at the top, different amounts of an oligonucleotide duplex containing
uracils were spotted onto the membrane to create a calibration plot (see Figure
22). This figure was originally published in (165) Shalhout et al. Genomic uracil
homeostasis during normal B cell maturation and loss of this balance during B
cell cancer development. Molecular and cellular biology. 2014;34(21):4019-32.
Reproduced from the American Society for Microbiology.
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Figure 24. Genomic Uracils in Murine Splenocytes
A

B

Figure 24. Genomic Uracils in Murine Splenocytes. (A) Quantification of
uracils in splenocyte DNA following stimulation with LPS. The fluorescence
intensities from a membrane similar to the one shown in Figure 23 were used to
quantify the uracils and were normalized with respect to the uracil amount in WT
splenocytes prior to LPS stimulation. In these and all other experiments reported
here, means and standard deviations of the results from triplicate samples are
reported. (B) Time course of genomic uracil levels in stimulated WT and AID-/splenocytes. Uracils were quantified and the data analyzed as described for A.
This figure was originally published in (165) Shalhout et al. Genomic uracil
homeostasis during normal B cell maturation and loss of this balance during B
cell cancer development. Molecular and cellular biology. 2014;34(21):4019-32.
Reproduced from the American Society for Microbiology.
In splenocyte B cell DNA from WT and AID-/- mice, there was no
detectable increase in the level of uracils during the five day ex vivo stimulation
time course (Figure 24A and B). This result was readily reproducible (see Figure
25A and B). This lack of difference in an increase in uracil accumulation between
WT (ie AID+/+) and AID-/- splenocytes throughout the LPS activation treatment
was surprising since studies have shown AID can lead to mutations in many nonIg genes and causes genome-wide translocations (177, 178). Similarly, there
was also no increase in the level of genomic uracils when splenocytes from
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MSH2-/- mice were activated (see Figure 23, 24A and 25). Thus, despite the role
of MMR in SHM and CSR (see section 1.2.3d, 1.2.4b and Figure 9) (178-180),
these results suggest that MMR is not the primary uracil repair pathway involved
in the removal of global uracils generated by AID across the genome. This result
is consistent with the well-established role of MMR in correcting replication errors
and with a previous study that compared relative effects of UNG-dependent
repair and MMR on SHMs in some AID target genes (178).
In contrast, a significant stimulation-dependent increase in uracils was
observed in UNG-/- splenocytes. Relative to unstimulated UNG-/- splenocytes,
the genomic uracil levels increased approximately 11-fold in UNG-/- splenocytes
within the first 3 days following LPS activation. This high uracil accumulation in
the genomes of UNG-/- splenocytes at day 3 was detected in repeated
experiments (see Figure 25). In some experiments, an increase of greater than
11-fold was observed (see Figure 25). The uracil level was then restored back to
the levels detected in unstimulated cells by the fifth day of the time course (see
Figure 23 and 24A, red line). The factors likely to contribute to the decrease in
genomic uracil levels beyond day 3 include a decrease in AID gene expression
after day 3, possible removal and/or repair of uracils by backup DNA
glycosylases such as SMUG1, and replicative dilution of incorporated uracils.
These data are qualitatively consistent with the increased uracil levels in the Ig
genes of stimulated UNG-/- B cells (163), but the magnitude of the increase I
detected is much greater than that reported previously. To demonstrate that the
presence of uracils was due to AID, I quantified genomic uracils in LPS-
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stimulated splenocytes from AID-/-UNG-/- mice. There was no detectable
increase in uracil levels in AID-/-UNG-/- cells following stimulation, while UNG-/cells stimulated in parallel with the double knock out cells acquired 15-fold-higher
levels of uracils within 3 days (see Figure 26). Together these data suggest that
splenocyte stimulation with LPS causes a rapid and large increase in genomic
uracil levels due to AID but that an UNG2-mediated repair pathway eliminates
the uracils in WT cells.
3.1.2 Time Course of the levels of AID and UNG2 Gene Expression during B Cell
Stimulation
Studies concerning the introduction of uracil by AID into the genome also
must consider the proteins involved in the removal or repair of those uracils. If
uracils are readily repaired by several pathways and uracil repair enzymes, AID
generated uracils may actually be underrepresented or escape detection. To
elucidate the balance between uracil creation by AID and uracil excision by BER,
mRNA levels of AID, UNG2, and SMUG1 genes were determined in the LPS
stimulated mouse splenocytes over a several day time course.
In activated splenocytes from WT, UNG-/-, and MSH2-/- genetic
backgrounds, AID gene expression levels increased ~20-fold relative to
unstimulated splenocytes. mRNA levels were normalized to the house-keeping
gene, GAPDH (glyceraldehyde 3-phosphate dehydrogenase) which was used as
an internal control in these studies (see section 2.1.4 for qRT-PCR details).
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Figure 25. Genomic Uracil Results are Reproducible

A

B

Figure 25. Genomic Uracil Results are Reproducible. (A) Independent
experiment showing a Ny+ membrane used for uracil quantification from a
different study with different mice samples than that shown in Figure 23 for
murine splenocyte and liver DNAs. Each labeling reaction contains equal
amounts of DNA spotted onto the membrane (350 ng) and the reactions were
done in triplicates. Stimulation with LPS was carried for three days. (B)
Quantification of uracils from part A. The numbers are normalized with respect to
the number for unstimulated WT cells (set to 1.0). Mean and standard deviation
are shown. Sp- splenocytes; Hp- hepatocytes. This figure was originally
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published in the supplementary material in (165). Reproduced from the American
Society for Microbiology.
Figure 26. Genomic Uracil Levels in AID-/-UNG-/- Splenocytes

Figure 26. Genomic Uracil Levels in AID-/-UNG-/- B cells. Relative genomic
uracil levels in LPS-stimulated splenocytes from UNG-/- and AID-/-UNG-/- double
knock out mice normalized to uracil levels in unstimulated WT splenocytes. This
figure was originally published in (165). Reproduced from the American Society
for Microbiology.
This sharp increase in AID gene expression upon stimulation occurred
during the first 3 days following stimulation and was reduced thereafter, never
quite reaching pre-stimulation levels by the end of the five day time course
(Figure 27). As expected, no AID mRNA was detected in the samples prepared
from the AID-/- cells (see Figure 27 B, blue line). In stimulated splenocytes from
WT mice, the rise and fall of UNG2 gene expression paralleled AID gene
expression. UNG2 and AID both increased approximately 20-fold compared to
levels in unstimulated cells during the first 3 days and declined thereafter (Figure
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27A). The increases in UNG2 mRNA levels following stimulation of WT
splenocytes were correlated with increases in single-strand-specific uracil
excision activities in both nuclear extracts (Figure 29) and whole-cell extracts
(Figure 30). UGI, a specific inhibitor of the UNG enzymes, almost completely
eliminated the uracil excision activity (Figure 29 and 30). Such upregulation of
UNG2 following B cell stimulation has been noted before (181).

Figure 27. Gene Expression in Stimulated Murine Splenocytes

Figure 27. Gene Expression in Stimulated Murine Splenocytes. The mRNA
levels of AID (blue), UNG2 (red), and SMUG1 (green) genes relative to the
GAPDH expression level (set at 100) are shown. The gene expression levels
were determined prior to and subsequent to LPS stimulation of splenocytes from
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WT (A), AID-/- (B), UNG-/- (C), and MSH2-/- (D) mice. This figure was originally
published in (165). Reproduced from the American Society for Microbiology.
3.1.3 Cytosine Deamination during B Cell Stimulation
Nuclear protein extracts and whole cell protein extracts were prepared
from WT and UNG-/- cells to test the cytosine deamination activity using a
fluorescently labeled single-stranded DNA substrate containing a cytosine within
the AID hotspot sequence motif, WRC (see section 2.1.8a for assay details). The
cytosine deamination activities were similar in the two types of cells and peaked
at day 3 following stimulation with LPS (Figure 28). Thus, both AID mRNA levels
and DNA-cytosine deamination activities follow the same general pattern of
increase and decline in the two genetic backgrounds. The increase in cytosine
deamination was seen using whole cell extracts as well as nuclear extracts.
However, of significance here is the increase in deamination activity upon
stimulation detected specifically in the nucleus because only nuclear AID can
lead to uracil accumulation in genomic DNA.
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Figure 28. Nuclear and Whole Cell Cytosine Deamination Activity
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Figure 28. Nuclear and Whole Cell Cytosine Deamination Activity. A time
course of DNA-cytosine deamination activity in nuclear extracts (A) and whole
cell extracts (B) prepared from LPS-stimulated splenocytes from WT (green) and
UNG-/- (blue) mice. Specific activity was calculated as picomoles of DNA
substrate converted to product per microgram of protein in the extract per minute.
Part A of this figure was originally published in (165). Reproduced from the
American Society for Microbiology.
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Figure 29. Nuclear Uracil Excision Activity

A

B

Figure 29. Nuclear Uracil Excision Activity. A fluorescently labeled DNA
oligomer containing uracil was incubated with nuclear extract from WT (A) or
AID-/- (B) LPS-stimulated splenocytes, and the specific activity of uracil excision
was determined. The activity was determined in the presence (+Ugi) or absence
(-Ugi) of the UNG enzyme inhibitor UGI.. This figure was originally published in
(165). Reproduced from the American Society for Microbiology.
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Figure 30. Whole Cell- Uracil Excision Activity
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Figure 30. Whole Cell- Uracil Excision Activity. A fluorescently labeled DNA
oligomer containing uracil was incubated with whole cell extract prepared from
WT (A) or AID-/- (B) LPS-stimulated splenocytes, and the specific activity of
uracil excision was determined. The activity was determined in the presence
(+Ugi) or absence (-Ugi) of the UNG enzyme inhibitor UGI.
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3.1.4 The Repair of Genomic Uracils during Normal B Cell Stimulation
Although UNG2 gene expression increased in AID-/- splenocytes following
LPS stimulation, the magnitude of the increase was smaller than in WT mice
(Figure 27A and B). In contrast to this result, a previous study using
transcriptome sequencing (RNA-Seq) found UNG expression to be about the
same in stimulated B cells from WT and AID-/- mice (182). To resolve this issue,
I determined the uracil excision activity in nuclear extracts (Figure 29) and whole
cell extracts (Figure 30) from AID-/- cells and found that it also peaked at day 3
post stimulation but that its magnitude was smaller than the peak activity seen in
WT cells (compare Figure 29A and B and Figure 30A and B). This activity was
eliminated when UGI was added to the reaction mixture, showing that it was
UNG specific. As predicted, no expression of UNG2 gene was detected In
UNG-/-splenocytes (Figure 27C). In MSH2-/- splenocytes, UNG2 gene
expression followed the same pattern as in WT cells (Figure 27D).
In contrast to UNG2 gene expression, there was no increase in the
expression of SMUG1 gene in any of the genetic backgrounds tested (Figure
27A through D). Similarly, splenocyte stimulation did not lead to large increases
in expression of other uracil-specific DNA glycosylases (TDG and MBD4)
following stimulation of WT splenocytes (see Figure 31). Thus, despite recent
reports that SMUG1 contributes more to uracil excision than UNG2 in mice (181)
and that SMUG1 contributes to CSR and SHM in mice (183), these results show
that UNG2 is the only uracil specific DNA glycosylase whose expression is
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upregulated in response to B cell stimulation. Thus, it must be responsible for the
repair of an overwhelming majority of uracils created by AID in stimulated WT B
lymphocytes. In other words, B cells undergoing maturation ex vivo display
homeostasis in genomic uracil levels.
Figure 31. Gene Expression Levels of Uracil Repair Proteins
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Figure 31. Gene Expression Levels of Uracil Repair Proteins. Expression
levels of AID (green), TDG (black), MBD4 (red), UNG2 (blue), and SMUG1
(purple) in LPS stimulated WT splenocytes were determined. qRT-PCR results
are shown above for unstimulated WT cells (day 0) and cells 3, 4, and 5 days
post-stimulation with LPS. The expression levels of the genes are relative to
GAPDH expression level and re-normalized to the gene expression levels at Day
0 (set to 1.0).This figure was originally published in (165). Reproduced from the
American Society for Microbiology
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3.1.5 Genomic Uracil Levels in Activated human Naïve B Lymphocytes
To extend these observations to human B cells, I purified mature naive B
cells from tonsil tissues obtained from two human donors and stimulated the B
cells ex vivo with anti-CD40 antibody and IL-4 to mimic the GC-reaction. The AID
expression and genomic uracil levels were determined in the cultured B cells
over a 7 day time course. AID expression increased substantially in both sets of
samples after 4 days of stimulation, but the magnitudes of the increase were
different in the two samples (Figure 32A). Regardless, the genomic uracil level
changed little over the 7 days in either sample (Figure 32B). This shows that, like
the WT murine splenocytes, normal human B cells maintain their genomic uracil
levels following stimulation despite an increase in AID expression. A similar
increase in the expression of UNG2 also increased upon stimulation (Figure
32C).
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Figure 32. Gene Expression Levels and Uracils in Human B Cells
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Figure 32. Gene Expression Levels and Uracils in Human B cells. Naive
mature B cells were isolated from tonsils from two independent donors and cells
were stimulated with anti- CD40 antibody and IL-4 for 7 days. AID (A) and UNG2
(C) expressions were normalized to GAPDH expression (with the day 0 level set
to 1.0). (B) The quantification of the genomic uracil levels in the ex vivostimulated tonsillar B cells relative to uracil levels in DNA from unstimulated cells
are shown (with the day 0 level set to 1.0). Panel A and B of this figure were
originally published in (165). Reproduced from the American Society for
Microbiology.
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3.2 AIM 2- Genomic Uracils in Cancerous B cells
The AID-dependent global uracil levels in B cell lymphoma genomes and
the uracil removal capabilities are examined. The genomic uracil homeostasis
found in normal activated B cells is lost in cancer cells where AID is constitutively
and ectopically expressed.
3.2.1 Uracil accumulation in murine B cell Lymphoma lines despite high UNG2
activity and expression
To determine whether the lack of uracil accumulation in the genome of
activated WT B cells was also true in germinal center-derived cancer cell lines, I
studied uracil accumulation in the genome of the CH12F3 cell line since it is a
murine B cell lymphoma-derived line that expresses AID upon stimulation with
CIT and switches from the IgM isotype to IgA (see section 1.1.1 for more details)
(1). The levels of genomic uracils and the expression of AID, UNG2, and SMUG1
genes in this cell line following its stimulation were determined and compared
with the pattern seen in WT and UNG-/- murine splenocytes.
Three days post stimulation, CH12F3 cells accumulated uracils in their
genome to a level about fourteen times the unstimulated level (Figure 33A). As
was observed in LPS-stimulated UNG-/- splenocytes (Figure 24A), the uracil
content decreased after day 3, returning to the unstimulated level by day 10.
To directly compare the uracil amounts in the genomes of these two types
of murine cells, equal amounts of DNA from primary WT and UNG-/- splenocytes
and from CH12F3 cells were labeled at uracil sites and the samples were spotted
on nylon membranes for quantification. A fluorescence scan of the membrane
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shows roughly equal intensities for DNA from UNG-/- splenocytes and CH12F3
cells after 3 days of stimulation (Figure 33B).
Figure 33. Uracil Levels in CH12F3 Stimulated Cells

CH12F3

B

Figure 33. Uracil Levels in CH12F3 Stimulated Cells. (A) Time course of the
change in genomic uracil levels in CH12F3 DNA with or without CIT stimulation.
(B) Fluorescence scan of a nylon membrane on which equal amounts of DNAs
labeled at uracil sites from unstimulated WT and UNG-/- mouse splenocytes and
unstimulated CH12F3 cells were spotted. DNAs from splenocytes stimulated with
LPS or CH12F3 cells stimulated with CIT for 3 days were labeled for uracil
quantification in parallel and also spotted onto the membrane. The panels in this
figure were originally published in (165). Reproduced from the American Society
for Microbiology.
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Quantification confirmed that the two sets of DNAs had similar levels of
uracil content and that these amounts were much higher than those seen with
the unstimulated CH12F3 cells and both unstimulated and stimulated WT primary
splenocytes (see Figure 34). Therefore, stimulated CH12F3 cells behave like
stimulated UNG-/- cells in terms of genomic uracil accumulation.
Both the AID and UNG2 expression profiles of CH12F3 cells were similar
to those of stimulated WT splenocytes (compare Figure 34 B, C and Figure 27A).
The kinetics of AID gene expression in CH12F3 cells was paralleled by nuclear
DNA-cytosine deamination activity (Figure 35), and the same pattern was seen
with UNG2 gene expression and nuclear uracil excision activity (Figure 36A and
B). Furthermore, the peak specific activities of cytosine deamination and uracil
excision in the nuclear extracts of CH12F3 cells were comparable to those in WT
splenocytes (compare Figure 28A with Figure 35 and Figure 29 with Figure 36B).
SMUG1 gene expression did not change detectably following CH12F3
stimulation, similar to ex vivo stimulated primary B cells (see Figure 37 and 27A).
Thus, CH12F3 cells accumulated uracils in their genome following their
stimulation despite the fact that their AID and UNG2 gene expression and
nuclear enzymatic activity profiles were similar qualitatively and quantitatively to
those in WT splenocytes.
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Figure 34. Uracil Levels in Primary B Cells versus CH12F3 Cells
A

C

B

Figure 34. Uracil Levels in Primary B Cells versus CH12F3 Cells.
(A) Genomic uracil levels in splenocyte DNA and CH12F3 DNA before and at
day 3 following LPS stimulation were determined. Levels are normalized to the
uracil content in WT cells prior to stimulation. (B) Direct comparison of AID
expression relative to GAPDH in WT splenocytes and CH12F3 cells. (C) Direct
comparison of UNG2 expression relative to GAPDH in WT splenocytes and
CH12F3 cells. qRT-PCR was done in parallel using the same primers. The
panels in this figure were originally published in the supplementary material of
(165). Reproduced from the American Society for Microbiology.
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Figure 35. AID expression and Nuclear Cytosine Deamination Activity in
CH12F3 Cells

Figure 35. AID expression and Nuclear Cytosine Deamination Activity in
CH12F3 Cells. Time course of change in AID gene expression and cytosine
deamination activity in nuclear extracts prepared from CIT-stimulated
CH12F3 cells. This figure was originally published in (165). Reproduced from the
American Society for Microbiology.
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Figure 36. UNG2 expression and Uracil Excision Activity in CH12F3 Cells
A

B

Figure 36. UNG2 expression and Uracil Excision Activity in CH12F3 Cells.
(A) UNG2 expression in CH12F3 cells relative to GAPDH gene expression (set at
100). (B) Time course of change in uracil excision activity in nuclear extracts
prepared from stimulated CH12F3 cells in the presence or absence of UGI. This
figure was originally published in (165). Reproduced from the American Society
for Microbiology.
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Figure 37. SMUG1 expression in CH12F3 Cells
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Figure 37. SMUG1 expression in CH12F3 Cells. SMUG1 expression in
stimulated (+CIT) and unstimulated (-CIT) CH12F3 cells relative to GAPDH gene
expression (set at 100).
To directly compare gene expression in CH12F3 cells with gene
expression in murine splenocytes, qRT- PCR was performed on equal amounts
of cDNA from the two cell types using the same set of primers and internal
controls. The results showed that in both of the cell types, AID and UNG2 gene
expression peaked at day 3 and the peak mRNA levels of both the genes were
about 20% to 30% lower in CH12F3 cells than in the splenocytes (see Figure 34
B and C). To compare the UNG2 excision activities of the two cell types, I
performed parallel uracil excision assays with nuclear extracts from WT
splenocytes and CH12F3 cells prior to stimulation and at 3 days following
stimulation and electrophoresed the products on the same gel. The gel showed
that CH12F3 cells had uracil excision activity comparable to that of WT
splenocytes (Figure 38). Thus, stimulated CH12F3 cells show AID gene
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expression, deamination activity, UNG2 gene expression, and uracil excision
activity similar to those seen in stimulated WT splenocytes but accumulate
uracils like stimulated UNG-/- splenocytes.
Figure 38. Nuclear Uracil Excision Activity is similar in Stimulated Primary
and CH12F3 B cells

Figure 38. Nuclear Uracil Excision Activity is similar in Stimulated Primary
and CH12F3 B cells. Uracil excision activity in nuclear extracts from stimulated
WT splenocytes (+LPS) and CH12F3 cells (+CIT). DNA containing uracil was
treated with the indicated amount of extract, and the products were
electrophoresed on a denaturing gel following strand cleavage. “Day 0” indicates
unstimulated cells, and “Day 3” indicates cells stimulated for 3 days. This figure
was originally published in (165). Reproduced from the American Society for
Microbiology.
The uracil accumulation detected in CH12F3 cells only occurs upon CIT
stimulation, and therefore induction of AID. However, some GC-derived cancers
constitutively and ectopically express AID (see TABLE 2). The J558 cell line, a
murine plasmacytoma cell line that constitutively expresses AID (184), was
chosen to investigate whether its genome contains uracils like the stimulated
CH12F3 cell genome. Both AID and UNG2 genes were expressed in J558 at
levels between unstimulated and stimulated WT splenocytes (Figure 39A). The
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J558 genome contained ~25-fold as much uracil as unstimulated UNG-/splenocytes, and this amount was less than what was found in the stimulated
UNG-/- splenocytes tested in parallel experiments (Figure 39B). Thus, this
murine cell line derived from a B cell myeloma expresses UNG2, but still exhibits
higher uracil content than B cells that have not undergone stimulation mimicking
maturation in germinal centers. These murine cancer cell line results suggest that
the loss of balance between uracil creation and elimination may be a common
feature of B cell cancers expressing AID.
Figure 39. J558 Gene Expression and Uracil Levels

Figure 39. J558 Gene Expression and Uracil Levels. (A) Gene expression
levels in J558 and splenocytes. Expression Levels of AID, UNG2 and SMUG1
were determined for stimulated and unstimulated WT and AID-/- splenocytes and
J558. The expression levels of the 3 genes are relative to GAPDH expression
level (set at 100).(B) Quantification of uracils in the genome of UNG-/- mice prior
to stimulation (-LPS) and at day 3 following stimulation (+LPS) compared to uracil
levels in the genome of the mouse plasmacytoma cell line, J558. Data from
triplicate samples are shown with error bars representing standard deviation.
(*** P< 0.0001)
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3.2.1 Uracil accumulation in human B cell Lymphoma lines
To determine whether the correlation observed between high AID levels
and high genomic uracil occurrence, despite high UNG2 expression, in murine B
cell cancers also extends to human B cell cancers, I studied 13 cell lines created
from human hematopoietic malignancies (see TABLE 4). Specifically, seven of
the cell lines tested are B cell lymphomas of GC origin, including two BL lines,
two

FL lines, and three DLBCL lines. In addition, a MM line and two T

lymphoma/leukemia lines were also studied. Finally, three cHL lines were also
studied. Although many cHL tumors show some evidence of GC development
(185), they usually do not express AID at high levels (137). PBMCs from healthy
blood of human volunteers were used as negative controls serving as non-AID
expressing B cells.
The GC-derived cell lines (ie. BL, FL, and DLBCL) had significantly higher
levels of AID expression and genomic uracils when compared to the non-GC
derived or characteristic cell lines. The BL, DLBCL, and FL cell lines express AID
at levels ranging from about 4 to 8% relative to GAPDH gene expression (Figure
40, top panel, closed bars). This is in contrast to the non-GC-derived lines, cHL
lines, and normal cells which had less than 1% AID gene expression (Figure 40
top panel, open bars). The nuclear DNA-cytosine deamination activities were
consistent with the AID mRNA levels in the cell lines (see Figure 40 and 41).
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Figure 40. AID Expression and Uracils in Human Lymphoma Cell Lines

Figure 40. AID Expression and Uracils in Human Lymphoma Cell Lines. AID
gene expression and genomic uracil levels in 13 human lymphoma-derived lines
and circulating human B cells. (Top) The AID expression levels are shown
relative to the GAPDH gene expression level (set at 100). Numbers on the x-axis
refer to the specific cell line detailed in TABLE 4. The asterisk indicates no
detectable expression. (Bottom) Genomic uracil levels relative to those in
circulating human B lymphocytes (set at 1.0). This figure was originally published
in (165). Reproduced from the American Society for Microbiology.
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Figure 41. Human Lymphoma Nuclear Cytosine Deamination Activity

Figure 41. Human Lymphoma Nuclear Cytosine Deamination Activity.
Nuclear cytosine deamination activity for some of the cell lines. The asterisks
indicate that no deamination activity was detected under these conditions. This
figure was originally published in (165). Reproduced from the American Society
for Microbiology.
The genomic uracil levels in the high-AID expressing cell lines, BL, FL,
and DLBCL, were quite high compared to the MM, cHL and T-cell lines.
Specifically, the GC-characteristic lines had genomic uracils 80- to 120- fold the
level found in normal PBMCs (Figure 40, bottom panel, closed bars). In contrast,
some of the low-AID B cell lines contained genomic uracils at levels that were
only two to five times those seen with normal PBMCs while the tested T cell lines
had uracil levels comparable to normal B cells (Figure 40, bottom panel, open
bars). When the genomic uracil levels in these cell lines were plotted against
their AID gene expression levels, the high-AID and low-AID lines clearly
separated into distinct groups (see Figure 42A). Stimulated tonsillar cells had
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somewhat higher uracil levels than peripheral B cells, and the low-AID lines had
uracil levels comparable to those found in the tonsillar cells (see Figure 42B).
Figure 42. Uracil versus AID in Human B Lymphoma Cell Lines
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Figure 42. Uracil versus AID in Human B Lymphoma Cell Lines. (A) The
genomic uracil levels in the human lymphoma cell lines are plotted against AID
mRNA expression levels. (B) The genomic uracil levels in naïve B cells purified
from tonsil donor 1 without stimulation and 4 days post ex vivo stimulation with
CD-40L and IL-4 are shown relative to levels in circulating normal B cell DNA
isolated from peripheral healthy donor blood. Normal B-cells are set to 1.0.
(mean ± S.D. from triplicates) The dashed lines indicate the upper and lower
values of the relative uracil levels for the low-AID group from Figure 5A to
indicate the genomic uracil level range found among the tested T-cell, classical
Hodgkins Lymphoma, and Multiple Myeloma cell lines. This figure was originally
published in the supplementary material of (165). Reproduced from the American
Society for Microbiology.
Since it is an inherent property of cancers to have genomic instability
(186), it was possible that the B cell cancer cell lines were not stable with regard
to genomic uracil content. In particular, it is possible that continual cytosine
deamination by AID increases the uracil content of high- AID cell lines with time.
However, when the Raji cell line was followed over many passages, no
consistent increase or decrease in the uracil content was observed (Figure 43).
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Thus, the B cell lymphoma- derived high-AID cell line displayed stable uracil
content, albeit at much higher levels than normal B cells.
Figure 43. Stable Uracil Levels in Raji

Figure 43. Stable Uracil Levels in Raji. Uracil levels in the Raji cell genome
over several passages. The uracil level in Raji cells at passage 1 (P1) was set at
100. This figure was originally published in (165). Reproduced from the American
Society for Microbiology.
3.2.2 Uracil excision activity in human B cell cancers overexpressing AID
One possible cause of elevated uracil levels in high-AID cell lines and
tumor samples is a reduction in uracil excision activity. To test this possibility, I
performed qRT-PCR measurements of UNG2 and SMUG1 mRNA in the human
cell lines in addition to uracil excision activity assays on several cell lines (Figure
44). The mRNA quantification studies showed that high-AID cell lines also
expressed UNG2 and SMUG1 genes at moderately higher levels than PBMCs
(Figure 44A). While the higher UNG2 expression seen in these cells was similar
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to the increased UNG2 expression seen in stimulated WT murine splenocytes
and CH12F3 cells, the increase in SMUG1 expression was not observed in
murine cells (Figure 27 and 37).
Figure 44. UNG2 expression and Uracil Excision Activity in human
lymphoma cell lines

Figure 44. UNG2 expression and Uracil Excision Activity in human
lymphoma cell lines. (A)The UNG2 and SMUG1 expression levels in the same
human cell lines as described for Figure 40 relative to the GAPDH expression
level.(B) Uracil excision activity in nuclear extracts prepared from a subset of the
human lymphoma cell lines in the absence UGI (left) or in its presence (right).
This figure was originally published in (165). Reproduced from the American
Society for Microbiology.
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I performed the uracil excision activity assay for two low- AID lines and
seven high-AID lines in the presence or absence of UGI. The high-AID nuclear
extracts showed 50% to 100% more uracil excision activity than the low-AID
extracts tested (Figure 44B, left panel). This activity was abolished when UGI
was included in the reactions (Figure 44B, right panel), confirming that it was due
to UNG2. Furthermore, the specific activities of the nuclear extracts from highAID cell lines were comparable to the peak activity seen in nuclear extracts from
murine splenocytes (compare Fig. 29 and 44B). These results show that the
UNG2 gene expression is not defective in high-AID human B cell cancer cell
lines and that they contain nuclear uracil excision activity comparable to that
seen with stimulated WT murine splenocytes. Despite this activity, they contain
very high levels of uracils in their genome.
3.2.3 Genomic uracil levels change with AID
To determine whether increases or decreases in the expression of AID in
human cell lines causes commensurate changes in genomic uracil levels, I used
previously generated variants of the Ramos cell line that express AID at different
levels (166).These included cell lines Ramos 7 (high AID gene expression) and
Ramos 1 (low AID gene expression) (166) and lines created through transfection
of a plasmid expressing AID into Ramos 1 (Ramos A.1, A.2, and A.5) or the
empty vector (Ramos C.1) (43).
The expression of AID was much higher in Ramos 7 than in Ramos 1 cells
and was higher in Ramos A.2 and A.5 cells than in Ramos C.1 cells (Figure 45,
top panels) as expected. Correspondingly, the genomic uracil level in Ramos 7
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cells was higher than in Ramos 1 cells, and there was a similar relationship
between genomic uracil levels in the Ramos A.2 and A.5 lines and in Ramos C.1
cells (Figure 45, bottom panels). Thus, Ramos-derived cell lines with higher AID
expression show a pattern of higher genomic uracil levels as seen in the highAID group of cell lines (Figure 40). To test whether the catalytic activity of AID
was required for the increase in genomic uracils, I transfected a catalytically
inactive version of AID (E58A) into Ramos 1 cells. Both WT AID and E58A AID
gene transfection increased AID mRNA levels (Figure 46, left panel), but only the
catalytically active version increased genomic uracil levels (Figure 46).
Figure 45. AID and Uracils in BL Ramos Derived Lines

Figure 45. AID and Uracils in BL Ramos Derived Lines. (Top panel) AID
expression in Ramos 1 and Ramos 7 lines and in the Ramos 1-derived lines
transfected with empty vector (Ramos C.1) or with an AID expression plasmid
(Ramos A.1, A.2, and A.5). (Bottom panel) Genomic uracil levels in the same cell
lines. In both cases, the numbers were normalized relative to uracils in normal
circulating human B cells (set to 1.0). The asterisks indicate undetectable
expression. This figure was originally published in (165). Reproduced from the
American Society for Microbiology.
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Figure 46. WT and E58A AID

Figure 46. WT and E58A AID. (Left panel) Relative expression levels of WT AID
and the AID E58A mutant following transient transfection of Ramos 1 cells. The
AID level in Ramos 1 transfected with an empty vector was set to 1.0. (Right
panel) Genomic uracil levels in the same transient-transfection experiment
relative to uracils in the empty vector control (set to 1.0). This figure was
originally published in (165). Reproduced from the American Society for
Microbiology.
Interestingly, UNG2 gene expression was highest in the three BL cell lines
expressing AID at very high levels, Ramos 7, Ramos A.2, and Ramos A.5 (see
Figure 47A). This suggests that when Ramos cells were transfected with AIDexpressing plasmids, endogenous UNG2 gene expression levels may have
lagged behind increasing AID expression levels, allowing the genomic uracil
levels to rise, but that the uracil excision ability eventually caught up with uracil
generation by AID stabilizing the genomic uracil content at a higher level than
before.
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Figure 47. Expression of Uracil Repair Enzymes in Human Cell Lines
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Figure 47. Expression of Uracil Repair Enzymes in Human Cell Lines. (A)
UNG2 and SMUG1 gene expression in Ramos-derived cell lines. mRNA levels
for Ramos 1 and Ramos 7 lines, and the Ramos 1-derived lines transfected with
empty vector (Ramos C.1) or with an AID expression plasmid (Ramos A.1, A.2
and A.5) are shown. The levels are normalized to GAPDH levels set at 100. (B)
UNG2 expression levels in AID-knockdown cell lines. UNG2 mRNA levels are
presented as percentage of mean values for the negative controls expressing
scrambled-shRNA. This figure was originally published in the supplementary
material of (165). Reproduced from the American Society for Microbiology.
To study the effects of reducing AID gene expression on genomic uracil
levels, I transformed human cell lines expressing AID at high levels with plasmids
expressing AID-specific shRNA. The levels of success of the knockdown (KD)
differed among the cell lines, but AID gene expression in all the lines was
reduced by 75% or greater compared to the expression seen with a control line
expressing scrambled shRNA (Figure 48, top panel). All the AID KD lines had
substantially reduced genomic uracil levels compared to their scrambled shRNA
counterparts, but the degrees of reduction were different for different cell lines
(Figure 48, bottom panel). The variability in the reduction in genomic uracil levels
among different KD lines may have been due to differences in genetic
backgrounds between the cell lines and the fact that they represent three
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different B cell lymphomas. For example, SMUG1 levels or dUTP pools may be
different in different cell lines and this may have secondary effects on genomic
uracil levels. It should be noted that UNG2 gene expression changed in the same
direction as the change in AID gene expression in these cell lines (see Fig.47B).
Figure 48. Knock-down of AID in Human B cell Lines

Figure 48. Knock-down of Human B cell Lines. Effects of AID knockdown on
human lymphoma cell lines. The AID mRNA levels and genomic uracil levels are
presented as the percentages of the mean values for the line expressing
scrambled shRNA. (Top panel) AID expression in cell line expressing AIDspecific shRNA. (Bottom panel) Genomic uracil levels in the same cell lines. This
figure was originally published in (165). Reproduced from the American Society
for Microbiology.
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3.2.4 Genomic Uracils in AID-expressing patient B cell lymphomas
I tested tumor samples from six pretreatment lymphoma patients (referred
to as patients P5 through P10) (see TABLE 5) and determined the levels of AID
gene expression and genomic uracil in the B lymphomas. AID gene expression
was higher in FL and DLBCL patient tumors than in the three MZL patient
samples (Figure 49A, open bars). MZL tumors are thought to originate from postGC marginal- zone B cells and thus, the low AID gene expression in these
tumors is consistent with their origin. The patients from whom the tumor samples
were obtained were unrelated individuals, and their cancers were at different
stages and had different cytogenetic markers (see TABLE 5). Consequently, it is
not surprising that the patients within each group (patients with DLBCL or FL and
patients with MZL) showed considerable variation in AID gene expression levels
(Figure 49A). Regardless, the genomic uracil levels were much higher in FL and
DLBCL tumors than in normal B cells and the MZL tumors. The uracil levels in FL
and DLBCL tumors were comparable to those seen in most FL and DLBCL cell
lines (compare Figure 40A and 49A, closed bars). In contrast, the MZL tumors
had amounts of uracils in their DNA that were only slightly higher than those
seen with normal B cells (Figure 49A, closed bars).
In addition, I also tested tumor samples from eight patients with CLL
(patients P1 through P4 and P11 through P14, see TABLE 5). CLL tumors are
known to be heterogeneous with respect to AID gene expression and I also
detected a range of AID gene expression in the CLL patient samples. In contrast,
there was little tumor-to-tumor variation in UNG2 and SMUG1 levels (Figure
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49C). However, there was a strong correlation between AID gene expression and
genomic uracil levels (Figure 49B). The correlation observed between elevated
AID gene expression and accumulation of uracils in the genomes of human cell
lines holds also for the patient tumor samples.
Figure 49. Gene Expression and Genomic Uracil Levels in Patient Tumor
Samples

Figure 49. Gene Expression and Genomic Uracil Levels in Patient Tumor
Samples. The patients and the numbering are described in TABLE 5. (A) AID
expression levels and uracil levels in lymphoma patient samples. Genomic uracil
levels are indicated relative to those in normal circulating human B lymphocytes
(set at 1.0). (B) AID expression levels and uracil levels in CLL patient samples.
(C) UNG2 and SMUG1 gene expression in the same CLL patient B cells.
Expression data are normalized to GAPDH expression set at 100. This figure
was originally published in (165). Reproduced from the American Society for
Microbiology.
3.3 AIM 3- AID- dependent DNA Damage in B cell Lymphomas
As discussed above, AID is essential for normal B cell development and
required for SHM and CSR (see section 1.1). The point mutations and strand
breaks introduced during these processes result from the actions of a number of
enzymes in addition to AID, including UNG, APE, MMR proteins, and TLS
polymerases (see section 1.2) (187, 188). Although the regulation of the AID
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gene and its transcript ensure that it is principally expressed in GC B cells,
results from Aim 1 of this work suggest that murine splenocytes (see section 3.1)
stimulated to overexpress AID introduce uracils at a large number of genes, not
necessarily restricted to the Ig genes. These uracils are subsequently eliminated
by an UNG-dependent excision repair process (165). Additionally, several
studies have shown that AID can target many non-Ig genes introducing
mutations including oncogenes such as MYC, PAX-5, PIM1, and BCL2 in B
lymphocytes (178, 189).
Results from Aim 2 reveal that B cell lymphomas that overexpress AID
maintain a high level of uracil in their genomes (165). To test whether the
downstream processing of the initial uracil lesions leads to an accumulation of
other types of DNA damage, I subjected human lymphoma cell lines that
overexpress AID and have high levels of genomic uracils to abasic site
quantification, single- and double strand break analysis, and cell viability studies.
Many of these cell lines contain high levels of these lesions in an AID-and Ungdependent manner. Furthermore, results suggest this accumulated DNA damage
may compromise genomic stability.
3.3.1 Expression of AID and accumulation of genomic uracils in cancer cell lines
I confirmed AID expression levels relative to TBP in six of the GC-derived
lymphoma cell lines used in Aim 2 (see Figure 50A). AID mRNA levels in FL,
DLBCL, and BL lines were 13 to 22 fold higher relative to the endogenous TBP
mRNA levels in each sample. This is in distinction to AID levels in the T cell
lymphoma and cHL cell lines where AID mRNA levels were below TBP
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expression. AID mRNA was not detected in B cells isolated from non-cancerous
donor peripheral blood. To specifically confirm deamination activity in the
nucleus, I prepared nuclear extracts from these cell lines to assay nuclear
cytosine deamination activities using a single-stranded fluorescently labeled DNA
oligo with a cytosine in the sequence context preferred by AID. When products
were electrophoresed following uracil excision of any deaminated cytosines and
abasic site cleavage with alkaline and heat treatment, nuclear cell deamination
activity was easily detected in the FL, DLBCL, and BL lines (Figure 50B, and
Figure 41). No deamination product was observed in the T-cell extracts while one
of the two tested cHL lines showed limited but detectable product. Thus, both the
nuclear DNA-cytosine deamination activities and the AID mRNA expression
levels are highest in the GC-characteristic B cell lymphomas confirming results in
Aim 2.
3.3.2 Accumulation of AP sites in cancer cell lines
The genomes of lymphomas expressing elevated AID levels contain an
excess of uracils in their genomes (see Figure 40), but these cells also express
SMUG1 and UNG2 genes at normal or higher than normal levels (see Figure
44A). This implies that SMUG1 and UNG2 enzymes will attempt to excise this
surplus of uracils establishing many abasic sites. Any subsequent processing of
abasic sites by AP endonucleases can create strand breaks. To study this, I
utilized a variety of biochemical assays.
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Figure 50: AID expression and Cytosine Activity in Human Cell Lines
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Figure 50: AID expression and Cytosine Activity in Human Cell Lines. (A)
The AID expression levels are shown relative to TBP. Asterisk indicates no
detectable expression in normal B-cells isolated from PBMCs of healthy donors.
(B) An oligonucleotide DNA containing cytosine in AID’s preferred sequence
context was treated with equal amounts of nuclear extracts from each cell line
and the products were electrophoresed on a denaturing gel following treatment
with E. coli UDG to excise any deaminated cytosines and nicking with alkaline
and heat treatment. The percent product is shown below the denaturing gel.
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I quantified the AP sites in the DNAs by using a previously established
method that also utilizes ARP (see section 2.1.6) (190). Briefly, endogenous
abasic sites are biotinylated with ARP, which allows for quantification of the AP
sites. It should be noted that this assay detects all aldehydic adducts in DNA
including intact AP sites, AP sites cleaved by AP endonuclease or other enzymes
and the formamido forms of a number of oxidation and alkylation-induced
damage (191). As there is no indication that the amount of oxidation and
alkylation damage to DNA changes when AID is abundant, I refer to the number
of all sites labelled during this assay as abasic or AP sites for textual
convenience. There are approximately 0.5 AP sites per million base pair in
normal B cell DNA (donor age range 20 to 30 years) and T cell and cHL lines
were found to contain slightly higher amounts at statistically insignificant levels.
Strikingly, 10 to 20 AP sites per million base pair were detected in the high AIDexpressing cell lines- FL, DLBCL, and BL. This is almost 20 to 40 fold higher than
normal B cell AP site levels (Figure 51). In these high-AID expressing cell lines,
there are one-fifth to one-tenth as many persistent AP sites as uracils in the
DNA.
To study the effects of reducing AID expression on accumulated AP sites,
I analyzed the level of AP sites in stable cell lines established by knocking down
the expression of the AID gene with AID-specific shRNA versus scrambledcontrol shRNA in select high AID expressing lines (see Figure 48). This reduction
in AID also reduced the detectable AP sites (Figure 52). A significant reduction in
the number of AP sites in the scrambled shRNA group when compared to the
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AID- knock down (KD) lines is observed. All of the high-AID expressing cell lines
had a higher number of AP sites than normal B cells, and in each case, the
number of AP sites did not exceed the number of genomic uracils in the DNA.
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Figure 51: AP Sites in Human Cell Lines
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Figure 51: AP Sites in Human Cell Lines. Abasic sites are quantified using a
biochemical detection method where DNAs are treated with aldehyde reactive
probe to label endogenous abasic sites, followed by labeling with Cy5streptavidin. (see Figure 19 for assay details). AP sites from cell line DNA were
quantified in parallel with DNA from healthy peripheral blood B cells (normal Bcells, age 20-30).
3.3.3 Accumulation of Single- and Double Strand Breaks
To examine if single- and double strand breaks in the genome change in
relation to AID levels, the Ramos 1 (low-AID) and Ramos 7 (high-AID) (see
Figure 45 top left for AID expression) cell populations were subjected to the
alkaline comet assay and a wide distribution of tail lengths was detected with tails
visually longer for Ramos 7 than Ramos 1 (A. Martin, D. Haddad, University of
Toronto) (Figure 53A and B). This is reflected in the quantified tail moments of
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these two cell lines, where Ramos 7 had about twice as high a tail moment as
Ramos 1.The tail moments of Ramos 1 cells increased to the level of Ramos 7
when the former cells were subjected to an ionizing radiation dose above 4 Gray
(Figure 53B). Therefore, the higher levels of AID in Ramos 7 are correlated with
a higher number of genomic single- and double strand breaks.

AP Sites per million bp

Figure 52: AP Sites in Human AID knock-down Cell Lines
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Figure 52: AP Sites in Human AID knock-down Cell Lines. AP sites were
quantified in DNAs from stable cell lines prepared by transfecting the parental
cell lines in Figure 51 with either a control scrambled shRNA (scrm) or an AIDspecific shRNA (KD) to knock down expression.
Following removal of dead and dying cells from the cultures, the low- and
high- AID expressing cell lines were stained with anti-γH2AX antibody to detect
the marker for DNA DSBs. The FL, DLBCL, and BL cell lines frequently showed
nuclei with several foci (Figure 54A, right panels). In contrast, the T-cell and cHL
lines had fewer nuclei positive for staining (Figure 54B, left panels). The number
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of foci per nuclei was counted using the Image J software and this confirmed the
conclusions drawn from visual observations (Figure 54B).
Figure 53: AID dependent Strand Breaks
A

B

Figure 53: AID dependent Strand Breaks. (A) Representative false color
alkaline comet assay images of Ramos 1 and Ramos 7 cells. Cells were
synchronized in G1 with mimosine. (B) Tail moments of ~100 cells of Ramos 1
and Ramos 7 are plotted. Ramos 1 cells were irradiated at indicated grays shown
below plot. Bars indicate median tail moment values. *** p< 0.05 (P value 0.009).
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Figure 54: γH2AX and Double Strand Breaks
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Figure 54: γH2AX and Double Strand Breaks. (A) (Left) Representative
images of low-AID expressing cells and (Right) high-AID expressing lines stained
for γH2AX (yellow). Cells were stained with DAPI (blue) and images merged. (B)
Quantification of γH2AX foci per nuclei in lymphoma cell lines. Foci per nuclei
were quantified for ~100 cells for each sample using ImageJ Software. Lines
indicate median foci per nuclei values. **** P<0.0001 comparing low AID
expressing foci and high-AID expressing foci.
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The fairly wide variation in the number of foci and the existence of cells
without any foci in every cell line population suggests that a single-strand break
generated during the repair of AID-introduced uracils is converted to double
strand breaks in only a fraction of the cells- possibly the cells actively replicating
their DNA. Regardless, there is a clear correlation between high AID expressing
cell lines and the accumulation of DSBs in their DNA.
To determine if the presence of DSBs is directly dependent on the
presence of AID, AID-KD cell lines and the corresponding shRNA-control lines
were also stained for γH2AX. A significant decrease in the mean number of foci
per nuclei was observed when comparing the quantification of γH2AX foci
staining of ~100 FL-KD cells with the FL-scrambled control cell line (Figure 55).
This same pattern of decrease was seen in the KD versus shRNA-control cell
lines established with DLBCL and BL lines (Figure 54) supporting AID’s role in
the promotion of the genome wide detected DSBs.
3.3.4 Overall Effect on Cell Viability
I initially noticed that the high-AID expressing cell lines grew at slower
rates than the low-AID expressing cell lines. Further, the accumulation of uracils,
AP sites, and strand breaks in the genomes of high-AID expressing cell lines
promote genomic instability and may lead to increased cell death. To determine if
this is the case, dead cells were removed and cultures with ~100% viability were
grown for three days, stained with Trypan Blue, and counted using a TC20
Automated Cell Counter (Bio-Rad). The results show a correlation between AID
expression and higher cell death. Cultures of cell lines with the highest AID
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expression levels, FL, DLBCL, and BL, had the highest percentage of inviable
cells (up to 30%), while those with the lowest AID levels, T-cell and cHL lines,
remained close to 90% viable (Figure 56A) with a lower percentage of dead cells.
Furthermore, by simply knocking down AID in the high AID-expressing cell lines,
cell viability was restored to >85% viability when directly compared to the
corresponding shRNA-control lines which maintain poorer viability grown under
the exact conditions (Figure 56B).

Foci per Nuclei

Figure 55. DSBs Reduced in AID Knock-downs
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Figure 55. DSBs Reduced in AID Knock-downs. Quantification of γH2AX foci
per nuclei in extablished cell lines where AID expression was knocked down (KD)
with shRNA targeting AID versus scrambled control shRNA (scrm). **** P<0.0001
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Figure 56. Viability of Human B Cell Lymphomas
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Figure 56. Viability of Human B Cell Lymphomas. (A) Percent viability in
human B cell lymphomas. (B) Restoration of viability in extablished cell lines
where AID expression was knocked down (KD) with shRNA targeting AID versus
scrambled control shRNA (scrm). **** P<0.0001
With an increase in genomic instability and cell death culminating from
AID-introduced uracils, I decided to determine the levels of uracils in inviable
cells to see if dead/dying cells accumulated larger amounts of uracils or if this
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population of cells has lower uracil levels from attempted repairs that
overwhelmed the cells and lead to apoptosis. Viable cells were isolated from
inviable cells in the FL, DLBCL, and BL cell lines using Annexin-V magnetic
beads and uracils were quantified. Surprisingly, in every case there were more
uracils in the genomes of inviable cells than viable cells (Figure 57). In most of
the cell lines, a two-fold or higher level of uracil was detected in the inviable
population as compared to the viable population.
Figure 57. Uracils in Viable and Inviable Human B Cell Lymphomas
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Figure 57. Uracils in Viable and Inviable Human B Cell Lymphomas. Relative
uracil levels in inviable cells of human B cell lines with the uracil levels in viable
cells set to 1.0 in each line tested.
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3.3.5 DNA Damage due to Attempted Repair by UNG
UNG enzyme is one of the principal defense mechanisms mammalian
cells have against accumulation of uracils in the genome, playing a major role in
the excision of this base (see section 1.2.3b) (192). To determine whether
accumulation of damage is effected specifically by the UNG glycosylase, I
expressed the UNG enzyme inhibitor UGI in the same FL, DLBCL, and BL high
AID-expressing cell lines. Although successful UGI expressing lines were created
from these tumor lines, individual clones derived from each line showed
considerable variability in growth. Some clones grew poorly or died off
suggesting that inhibition of UNG2 enzyme in these cells beyond a certain level
may be toxic. Regardless, I was able to establish cell lines with less than 50%
uracil excision activity compared to corresponding cells transfected with the
empty vector (EV) control from each of the five high AID-expressing lymphoma
cell lines (Figure 58A, Top panel). Expression of UGI caused the genomic uracil
levels to go up by ~30% (Figure 58A, Bottom panel). This confirms that UNG2 is
one of the principal enzymes that helps eliminate the uracils created by AID in B
cell lymphomas.
The removal of uracils by UNG enzyme results in abasic sites (see Figure
12). It reasons that if AP site accumulation is due primarily to the attempted
repair of the AID-introduced uracils, then a reduction in this repair may reduce
AP site accumulation as well. With inhibition of UNG in these UGI-expressing
cells, a 2 fold to 4-fold reduction in the number of AP sites was observed when
comparing the cell lines expressing empty vector to their UGI-expressing
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counterparts (Figure 59). A similar reduction was observed in the γH2AX foci in
the nuclei of those cells expressing UGI (Figure 60). This significant decrease in
accumulated DSBs further implicates the attempted repair of uracils by UNG as
one pathway that leads to genomic instability in these high- AID expressing cell
lines.
Figure 58. Uracils in Human B Cell Lymphomas Expressing UGI
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Figure 58. Uracils in Human B Cell Lymphomas Expressing UGI. (Top panel)
Uracil Excision activity assays were performed on the UGI expressing cell lines
and the corresponding cells lines expressing an empty vector (EV). The specific
activity of uracil excision in the EV-expressing cells was set at 100%.(Bottom
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panel) The genomic uracils were quantified in the UGI- expressing cell lines and
the EV-expressing (set at 100%).
Figure 59. AP Sites in Human B Cell Lymphomas Expressing UGI

Figure 59. AP Sites in Human B Cell Lymphomas Expressing UGI. AP sites
were quantified in the FL, DLBCL, and Burkitt lymphoma cell lines transfected
with an empty vector (EV) or a plasmid expressing UGI (UGI).
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Figure 60. DSBs in Human B Cell Lymphomas Expressing UGI
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Figure 60. DSBs in Human B Cell Lymphomas Expressing UGI. γH2AX foci
per nuclei were quantified with Image J for cell lines expressing UGI or the empty
vector (EV) for ~50 cells per line. **** P<0.0001
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Figure 61. Percent Viability Compromised further in Human B Cell
Lymphomas Expressing UGI
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Figure 61. Percent Viability Compromised further in Human B Cell
Lymphomas Expressing UGI. Percent viability of six independent cultures each
was determined for FL, DLBCL, and BL cell lines expressing UGI or the empty
vector (EV) using the Trypan Blue Exclusion assay. Lines indicate median
percent viability.
Finally, with a reduction in uracils, AP sites, and DSBs, I expected the
UGI-expressing cell lines would restore cell viability due to reduction in overall
genomic instability. However, when the cells were subjected to the Trypan Blue
exclusion assay, an even higher percent of cell death approaching nearly ~50%
(Figure 61) in the UGI-expressing FL, DLBCL, and BL established lines was
observed. This reduction in cell viability may be an indicator that the reduction of
repair of the uracils by partially inhibiting UNG leads to toxic and overwhelming

133

mutations throughout the genome that may actually result in poor propagation of
the cell lines.

134

CHAPTER 4: DISCUSSION
Figures and portions of the text in this chapter were reprinted or adapted in
compliance with the ASM Journals Statement of Authors’ Rights from:

Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS.
Genomic uracil homeostasis during normal B cell maturation and loss of this
balance during B cell cancer development. Molecular and cellular biology.
2014;34(21):4019-32. doi: 10.1128/MCB.00589-14.
4.1 Loss of Genomic Uracil Homeostasis in AID-expressing B Cell
Lymphomas
AID’s role in the adaptive immune system is an exceptional biological
process since it is the only identified mechanism in which cells intentionally
require damage to genomic DNA sequences to achieve benefit to the organism.
Previous reports established the hypothesis that AID is a cytosine deaminase
based on genetic studies as well as in vitro biochemistry. Cells are equipped with
several repair pathways that excise uracils, but in the process, may lead to base
substitutions and strand breaks. However, prior to this work, the specific
relationship between AID- generated uracils and their subsequent excision by
UNG or MMR had not been examined in normal B cell development or B cell
lymphomagenesis. This research examined the interplay and resulted in novel
findings and conclusions.
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4.1.1 First Demonstration of Uracil Accumulation in Splenocyte Genomes
This study revealed that UNG-/- splenocytes acquire a substantial level of
uracils upon AID activation through stimulation and that this rise in uracils was
not seen in AID-/- splenocytes (Figure 26). Although an accumulation in genomic
uracils was not entirely surprising since AID has been shown to be a DNAcytosine deaminase in vitro (11-14), this study is the first to directly demonstrate
AID-dependent uracil accumulation in the genomes of B lymphocytes undergoing
activation. In addition, transient-transfection studies revealed that the catalytic
activity of AID was required for its ability to increase genomic uracil levels (Figure
46). While another contributing factor to genomic uracil accumulation may be due
to high transcription levels in stimulated B cells possibly leading to increased
dUTP incorporation during replication, as was recently shown to be the case in
yeast cells (193), the research described here clearly demonstrates that the
deamination of cytosines in DNA by AID leads to the increase in genomic uracils
of stimulated B lymphocytes (165).
The large increase in uracil accumulation suggests that the majority of the
cytosines deaminated by AID are outside the Ig genes. In LPS treated UNG-/splenocytes, the genomic uracil content increased from 11 to 60 fold (Figure 24A,
26, 25B and 34A). There was variation in the level of the genomic uracil increase
seen in B cells from independent mice but an increase of at least 11 fold or
higher was always detected and reproducible. The uracil quantification assay
was always done by assaying DNA samples in triplicate, processing all the
compared samples in an experiment in parallel, applying them to the same Ny+
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membrane, and always alongside the uracil standard (Figure 23, 25A, and 33B).
However, uracil content is reported here as fold changes and not uracils per
million base pair because this assay uses a convenient synthesized duplex oligo
as the uracil standard which does not represent true physiological DNA. In
addition, previous studies using various uracil detection techniques have
reported anywhere from 200 (194) to 15,000 (195) uracils in the unstimulated
PBMC genome. Therefore, there may be around several thousand uracils per
haploid genome in stimulated B cells deficient in UNG. Recently, only one uracil
per kilobase was reported in the Ig genes (25) following B cell stimulation. Thus
the majority of the uracils introduced by AID in stimulated UNG-/- B cell are in
non-Ig genes.
4.1.2 Homeostasis in Uracil Creation and Excision Upon B Cell Stimulation
In ex vivo stimulated WT mouse B cells and human naïve mature B cells,
uracils created by AID were efficiently eliminated with no detectable uracil
increase resulting. Surprisingly, the level of genomic uracils in LPS activated
mouse WT B cells was comparable to the level detected in AID-/- B cells (Figure
24B). I also confirmed that there was no detectable uracil increase in murine WT
B cells upon IL-4 and LPS ex vivo stimulation which results in a different isotype
switching than LPS alone (Figure 62). This lack in increased global genomic
uracil accumulation in stimulated WT splenocytes suggests that UNG2 removes
the uracils introduced by AID quickly and efficiently. Thus, a genomic uracil
homeostasis exists in B lymphocytes undergoing the GC-reaction and antibody
affinity maturation (Figure 63, upper panel).
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4.1.3 B Cell Lymphomas Accumulate Uracil despite UNG2 Activity and
Expression
The high uracil accumulation detected in murine and human B cell
cancers overexpressing AID suggests a lack of efficiency in the ability of UNG2
to remove uracils introduced by AID. Initially, to explain the increase in uracil in
lymphoma genomes, I simply reasoned that (1) either AID was expressed at
much higher levels in lymphomas than activated WT B cells, or that (2) UNG2
was expressed at far lower levels in lymphomas. Experiments showed neither of
these to be the case when studying the proteins at the expression or activity
level. While an increase in the level of genomic uracils was only detected in
stimulated primary B cells deficient in UNG, lymphomas accumulated high uracil
levels but expressed UNG2 at normal or higher than normal levels and had
robust detectable nuclear uracil excision activity. Specifically, nuclear excision
activities in LPS-activated WT B cells and lymphoma cell lines overexpressing
AID were similar (see Figure 29A, 36B, and 44B). The same was true for AID
expression levels. In post-day 3 CIT stimulated CH12F3 B cells, the AID gene
expression in CH12F3 cells and WT splenocytes were at comparable levels (see
Figure 34B). Despite similar UNG2 and AID in WT and CH12F3 cells, only
stimulated CH12F3 cells accumulated uracils in their genome. Strikingly, in
Ramos 1 cells transfected to express AID at higher levels, the expression of
UNG2 increased but the uracil levels increased as well (Figure 45A and 47A).
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4.1.4 Why does uracil accumulate despite presence of functional UNG2?
Several possibilities may explain the observed disconnect between the
uracil excision activity of UNG2 and the accumulated genomic uracils in
lymphomas. UNG2 is primarily involved in removing uracils incorporated during
replication by polymerase utilization of dUTP to initiate canonical BER (see
Figure 10) (181, 196).Thus, the involvement of UNG2 in promoting mutations and
strand breaks in B cells may require specialized recruitment to the genes
targeted by AID. The factors involved in successful recruitment involve specific
chromatin modifications, post translational protein modifications, and the help of
molecular chaperones. It is known that when the Ig locus undergoes SHM and
CSR, the local chromatin undergoes specific epigenetic modifications (197), and
a recruitment protein may bring UNG2 to the modified chromatin. Alternatively,
since AID acts on transcribed genes (198), UNG may be associated or recruited
with the transcription elongation complex. For example, Rev1, a TLS
polymerase, has recently been shown to play a non-catalytic role in recruiting
UNG2 to S regions specifically being targeted by AID during CSR (89).
Additionally, specific phosphorylation of UNG2 may be involved in promoting its
pro-mutagenic role in adaptive immunity (199). The accumulation of uracils in
stimulated CH12F3 cells suggests that although UNG2 is present and nuclear
excision activities are robust, one of these recruiting or modifying factors may be
deregulated in lymphomas.

139

Figure 62. Ex Vivo Stimulation of Murine B Cells with LPS and IL-4
A

B

C

Figure 62. Ex Vivo Stimulation of Murine B Cells with LPS and IL-4. (A) AID
expression following stimulation with LPS+IL-4. (B) UNG2 expression following
stimulation with LPS+IL-4. (C) Genomic uracil levels following stimulation with
LPS+IL-4 normalized to WT levels prior to stimulation. This figure was originally
published in the supplementary material of (165). Reproduced from the American
Society for Microbiology.
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Figure 63. Homeostasis in Genomic Uracil Creation and Excision

Figure 63. Homeostasis in Genomic Uracil Creation and Excision. (Top
panel) Homeostasis during normal B cell development in germinal centers. Uracil
creation by AID and uracil excision by UNG2 are kept in balance during normal B
cell-development, resulting in low genomic uracil levels. (Bottom panel) The
balance between uracil creation and removal is lost during the development of
pre-cancer B cells in favor of uracil creation. This is a “DNA repair crisis” for the
precancerous cells leading to accumulation of mutations and strand breaks in
addition to uracils and resulting in genomic instability. This may lead to cellular
transformation. When uracil removal equalizes with uracil creation, stable
lymphoma or leukemia cell lines are established. These cell lines maintain the
high uracil levels introduced during the repair crisis. This figure was originally
published in the supplementary material of (165). Reproduced from the American
Society for Microbiology.
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4.1.5 High yet Steady Levels of Uracils in Lymphoma Cell Lines
As noted before, the uracil levels in the Raji cell line do not greatly
fluctuate over time (see Figure 43) suggesting that the high AID-dependent uracil
levels are stable. One may predict that if AID continues to introduce genomic
uracils with the levels continually rising in lymphomas, cells may develop
deleterious genomic instability due to the accumulation of mutations and strand
breaks. Therefore, this study suggests cell lines may only be able to be
immortalized from high-AID expressing B lymphomas, if a balance between
creation of genomic uracils and their excision is reached. This results in a new
steady-state stable uracil level in the cell line. However, this cell line steady-state
uracil level is higher than that found in normal B cells and does not represent
homeostasis in genomic uracils.
4.1.6 Possible DNA-repair Crisis disrupts Genomic Uracil Homeostasis
Increasing the expression of AID in B cell lymphomas or knocking it down
results in increasing genomic uracils levels or decreasing them, respectively
(Figure 45, 46, and 48). Drawing from these results, it is easy to envision some B
cells lose the balance between uracil introduction and removal during the GCreaction possibly due to impaired targeting of UNG2 to uracils introduced by AID.
This may result in an impaired ability to efficiently remove uracils created by AID
in a timely manner resulting in a “DNA repair crisis” (Figure 63, lower panel). If
this crisis persists it may result in high genomic instability, acquisition of
mutations, and possible apoptosis if the cell cannot repair the damage effectively.
However, during cell line establishment the uracil excision capabilities eventually
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catch up with introduced uracils resulting in the establishment of a stable cell line.
This results in a new steady-state condition where the genomic uracil levels are
much higher than the level in unstimulated WT B cells (Figure 63, lower panel).
In contrast, patients with B cell lymphomas/leukemias may still exhibit instability
from this DNA repair crisis with no stability acquired in AID, UNG2, and genomic
uracil levels. These levels may change overtime and under treatment and may
differ among patients resulting in variation from cancer to cancer (Figure 49A and
B).
An imbalance between AID creating uracils and UNG2 removing uracils in
favor of AID would result in an increase in the frequency of base substitutions
and mutations. In UNG-/- cells, the lacI and HPRT genes were shown to acquire
mutations at 1.5 and 5-fold higher the rates found in normal cells respectively
(196, 200). With the increased expression of AID upon B cell activation, any
deficiency in UNG and thus uracil excision may increase mutations. If these
mutations are in proto-oncogenes or tumor suppressors, lymphomagenesis may
ensue. In fact, UNG-/- mice have been shown to develop B cell lymphomas 20fold higher than WT mice and have a shorter life expectancy (201). In addition,
human follicular lymphomas have recently been shown to continually acquire AID
dependent mutations in the variable region as well as non-Ig genes during the
evolution of the patient’s cancer (128). Other members of the APOBEC family of
proteins have also been implicated in promoting cancers and mutations.
Sequencing of several tumor genomes has revealed these cancers accumulate
mutations with an AID/APOBEC ‘signature.’ These include cancers originating in
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the cervix, breast, and bladder, as well as of B cell origin (161, 162, 202).
Furthermore, many breast cancer patient tumor samples and cell lines have been
shown to overexpress APOBEC3B with at least two cell lines recently found to
have elevated uracil levels (203). If the development of non-GC derived
lymphomas overexpressing other APOBECs also involves the type of DNA repair
crisis depicted in Figure 63, then an understanding of how the activation of
normal B cells and their maturation may result in an imbalance between AID
generated uracils and uracil excision by UNG2 may be critical to understanding
how these cancers develop as well.
4.2 AID-dependent Accumulation of Specific DNA Damage in B cell
Lymphomas
4.2.1 DNA damage caused by AID and UNG
This work has demonstrated that high-AID expressing cell lines
accumulate large amounts of genomic uracil introduced by AID (165).
Furthermore, the attempted repair of these uracils by UNG2 leads to a consistent
pattern of AID expressing lymphomas accumulating high levels of DNA damage.
The specific types of DNA lesions, including AP sites and strand breaks, are
predicted to arise at each subsequent step of removal or attempted repair of
uracils (see model presented in Figure 64). In fact, a reduction in UNG repair is
met with a decrease in the downstream DNA lesions (AP sites and DSBs) in
these high AID-expressing lymphomas. Another finding of this study is that
inviable cells accumulate even more of the initial uracil lesion (Figure 57). This
implicates that dead/dying cells may have overwhelming levels of uracils,
possibly mutating genes essential to cell survival. These uracils continue to
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accumulate and escape repair and may destine the cell to apoptose. Further
studies are required to determine if the high uracil load signals programmed cell
death.
Figure 64. Model of DNA Damage Accumulation in High-AID Expressing
Lymphomas

Figure 64. Model of DNA Damage Accumulation in High-AID Expressing
Lymphomas. AID introduces the initial uracil lesion. Uracils that escape repair or
removal by such repair proteins as UNG2 accumulate throughout the genome.
However, some uracils are recognized and excised by UNG2 producing higher
than normal levels of AP sites in the DNA. The nicking of these sites by APE can
lead to SSBs and eventually DSBs resulting in genomic instability and poor cell
viability. Thus, this damage is dependent on AID and UNG.
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4.2.2 Mechanism of Accumulated DNA damage in Lymphomas
The mammalian system is equipped with several repair mechanisms and
enzymes to address uracils introduced in DNA. Four different glycosylases,
UNG, TDG, MBD4, and SMUG1 (see TABLE 1) can excise uracils in DNA during
base excision repair resulting in abasic sites. These AP sites can then be nicked
by AP endonucleases (APE1/2) leading to single strand breaks and eventually
double strand breaks. The increase in the number of AP sites observed in the
genomes of these high-AID expressing cell lines may result from incomplete
repair following excision by uracil glycosylases (see Figure 64). The
accumulation of single- and double strand breaks may arise following incomplete
repair of the nicking of these AP sites by APE. Furthermore, it is more likely that
these DNA lesions are distributed at a large number of sites in the genome and
not restricted to the Ig region, the major target of AID. When UNG is partially
inhibited by expressing UGI, these cells accumulate higher uracil loads due to
decreased repair abilities. However, less AP sites and DSBs are detected which
supports the notion that these lesions arise in part, due to attempted removal by
UNG. Cell viability, however, suffers with the reduction in repair in these high-AID
expressing lymphomas. This may be caused by an increase in the mutational
load of essential genes in the genomes due to escaped uracil repair that leads to
interruptions in normal cell functions.
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4.2.3 DNA Damage may promote Lymphomagenesis
It is well established that the translocation of c-myc, bcl-2, bcl-6 and other
genes to the Ig gene loci are a hallmark of B cell malignancies (204).
Additionally, in studies of B lymphocytes where translocations were induced by
creating a designed break in the IgH or c-myc genes, the other break was
created by AID and was found to lie at a large number of sites spread throughout
the genome (205, 206). As AID is required for the translocation of the c-myc
gene to the IgH locus (107), it is generally assumed that AID is involved in
converting cytosines to uracils at these genes and that the newly introduced
uracils are somehow converted to DSBs that are the cause of these
translocations. It is attractive to suggest that the damage identified in this study is
the source of DSBs that result in genome-wide translocations when AID is
overexpressed in B lymphocytes (205, 206) including those that aid oncogenic
transformation and lead to mutations in non-Ig genes (178). Like the
accumulated uracils, future studies that determine the sequence of DNA
fragments containing abasic sites and strand breaks found in these cancer
genomes will clarify whether they are the direct cause of translocated genes
found in these cells.
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4.2.4 Future Directions
These findings point to new avenues for treating GC-derived lymphomas
as these cells contain a large number of DNA modifications that are largely
absent in normal cells. For example, once the mechanism underlying the
observation that cells with higher uracils, AP sites, and strand breaks are prone
to apoptose is better understood, it may be possible to exploit this phenomenon
to selectively kill tumor cells highly expressing AID. For example, the
accumulated types of DNA damage described here may be exacerbated by
treatment with chemotherapeutic agents that lead to similar lesions. This may
overwhelm the cells and result in cell arrest or death quicker or with lower doses
of the chemotherapy since endogenous DNA damage persists already. In
addition, the fact that B cell lymphomas accumulate uracils and therefore require
functional BER for their removal and repair, it may make BER a target for
chemotherapy. For example, methoxyamine, which is utilized in the uracil
quantification assay to block endogenous abasic sites (see Figure 21), is also
currently studied as part of a combination anticancer chemotherapy regimen
when cancers are also treated with an alkylating agent such as Temozolomide
(207). The alkylating agent promotes damage to the DNA bases that are then
able to be excised by a DNA glycosylase resulting in AP sites. This allows Mx to
react to these AP sites and therefore inhibits repair, leading to cell death. Several
NCI-approved clinical trials using Mx in combination therapies are currently under
investigation

(NCT00892385,

NCT01658319

and

NCT00692159,

clinicaltrials.gov). Since B cell lymphomas already have endogenous damage in
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the form of high levels of uracils and AP sites this strategy may be worth
investigating specifically in high-AID expressing B cell lymphomas as well as
other high-APOBEC expressing cancers. In addition, other drugs that bind to AP
sites and inhibit repair should also be considered.
The high accumulation of uracils in B cell cancers may also be used as a
diagnostic marker for GC-derived lymphomas in addition to routine practices
such as determining the cytogenetics and chromosomal abnormalities in the
cancer. Furthermore, the accumulation of uracils and mutations should be
explored as the possible cause for the common drug resistance observed in the
treatment of some high-AID expressing cancers (208).
Future experiments need to be carried out to determine the molecular
cause for the imbalance seen in uracil accumulation and excision in lymphomas.
For example, UNG2 is present and active in these cells at normal or above
noraml levels. Thus, it is possible that deregulation of recruitment of UNG2 to the
AID-generated uracils is the culprit.
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ABSTRACT
THE LOSS OF GENOMIC URACIL HOMEOSTASIS AND AID-DEPENDENT
ACCUMULATION OF DNA DAMAGE IN B CELL LYMPHOMAS
by
SOPHIA SHALHOUT
May 2015
Advisor: Dr. Ashok S. Bhagwat
Major: Chemistry (Biochemistry)
Degree: Doctor of Philosophy
Activation-induced deaminase (AID) is a sequence-selective DNA cytosine
deaminase that introduces uracils in immunoglobulin genes. This DNA mutator is
required for somatic hypermutation and class switch recombination- processes
involved in the affinity maturation and diversification of antibodies. AID, however,
can

also

lead

to

deleterious

mutations

and

translocations

promoting

lymphomagenesis. The introduction of uracils throughout the genome of
activated B cells and the ability of UNG2 glycosylase to excise these uracils is
examined here. This interplay was also studied in cancerous B cells, with
different results emerging in transformed cells versus healthy cells. Genomic
uracil levels are found to remain at the same level in normal B cells stimulated to
express AID. However the increase in uracils by 11- to 60- fold detected in
stimulated B cells deficient in UNG, suggests that normal B cells do accumulate
high levels of genomic uracils. However, these uracils are efficiently and
effectively removed in UNG proficient cells, suggesting a balance or homeostasis
between uracil creation and elimination. Interestingly, murine B cell cancer lines,
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human B cell cancer cell lines, and several human B cell patient tumors from
several types of lymphomas overexpressing AID, were found to accumulate
genomic uracils at levels comparable to those seen in activated UNG-/- B cells.
These lymphoma/leukemia cells are not defective in uracil removal and express
UNG2 gene at the same level in normal peripheral B cells or higher. In addition,
they also have similar nuclear uracil excision activities suggesting uracils
accumulate despite robust uracil excision capabilities. These results suggest that
the homeostasis of uracil introduction and excision seen in normal stimulated B
cells is disrupted in lymphomas overexpressing AID despite UNG2 expression
and activity, resulting in the accumulation of high levels of genome wide uracils.
The majority of human B cell lymphomas do in fact derive from cells that
have undergone the germinal center reaction and are associated with the
expression of AID. The high levels of uracils that accumulate in the genomes of B
cell lymphomas suggests other types of DNA damage may also be present in an
AID-dependent manner as the cell attempts to remove and repair these uracils.
Here, we see that human B cell lymphoma cell lines that contain high uracil loads
also accumulate elevated levels of other types of genome wide DNA damage
dependent on AID. These include abasic sites and single- and double-strand
breaks. In addition, the accumulation of DNA lesions reduces cell viability. These
lesions are due in part to the attempted repair of uracils by uracil DNA
glycosylase.
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